Shigella: Antibiotic-Resistance Mechanisms And New Horizons For Treatment

Abstract: Shigella spp. are a common cause of diarrheal disease and have remained an important pathogen responsible for increased rates of morbidity and mortality caused by dysentery each year around the globe. Antibiotic treatment of Shigella infections plays an essential role in reducing prevalence and death rates of the disease. However, treatment of these infections remains a challenge, due to the global rise in broad-spectrum resistance to many antibiotics. Drug resistance in Shigella spp. can result from many mechanisms, such as decrease in cellular permeability, extrusion of drugs by active efflux pumps, and overexpression of drug-modifying and -inactivating enzymes or target modification by mutation. Therefore, there is an increasing need for identification and evolution of alternative therapeutic strategies presenting innovative avenues against Shigella infections, as well as paying further attention to this infection. The current review focuses on various antibiotic-resistance mechanisms of Shigella spp. with a particular emphasis on epidemiology and new mechanisms of resistance and their acquisition, and also discusses the status of novel strategies for treatment of Shigella infection and vaccine candidates currently under evaluation in preclinical or clinical phases.

Keywords: Shigella, antibiotics, resistance, drug resistance, mechanism, treatment, biofilm, efflux pumps, prevention, vaccine

Introduction
Shigella spp. are a Gram-negative, rod-shaped, immotile, and non-spore–forming bacteria and a causative agent of acute diarrhea that may progress to bloody mucoid diarrhea, also known as bacillary dysentery (or shigellosis). Shigella is the most common cause of diarrheal disease and has remained a major pathogen responsible for increased rates of morbidity and mortality caused by dysentery each year around the globe, particularly affecting children aged <5 years in developing countries.

The four types of Shigella spp. comprise subgroup A (S. dysenteriae), subgroup B (S. flexneri), subgroup C (S. boydii), and subgroup D (S. sonnei). Each subgroup contains several serotypes. Shigellosis can occur in pandemic, epidemic, and sporadic forms. Epidemiological reports have shown that the epidemic subgroup of diarrhea typically occurs as a result of infection with S. flexneri in developing countries and S. sonnei in industrialized countries.

Shigellosis is a great public health threat, because its infective dose is on the order of 10–100 organisms compared to other enteric pathogens (usually it is 105–108 for Salmonella and Vibrio, respectively).
Antibiotic treatment of common bacterial infections plays an important role in reducing prevalence and death rates of the disease. However, incorrect antibiotic use or overuse in treating diarrhea increases antibiotic resistance. *Shigella* spp. are resistant to most antibiotics, and drug treatment related to these bacteria is costly, time-consuming, and sometimes problematic, particularly in areas with limited medical care. About half the strains of *Shigella* in many parts of the world are now resistant to multiple drugs. Recently, various antibiotic-resistance mechanisms have been described by researchers, and these antibiotic-resistance mechanisms limit therapeutic options for treatment of *Shigella* infections.

Drug resistance in *Shigella* spp. can result from many mechanisms, such as extrusion of drugs by active efflux pumps, decrease in cellular permeability, and overexpression of drug-modifying and -inactivating enzymes or target modification by mutation. The current study was done to review various antibiotic-resistance mechanisms of *Shigella* spp., with a particular focus on epidemiology and new mechanisms of resistance and their acquisition, and also to discuss treatment and prevention measures for diseases caused by these organisms.

**Search Strategy**

We searched the biomedical electronic databases Web of Science, Scopus, PubMed (Medline), Embase, Cochrane Library, and Google Scholar for articles on *Shigella* published in English between 1990 and May 2019, using the key terms (alone and in combination) “*Shigella*”, “drug resistance”, “mechanism”, “biofilm”, “efflux pump”, “vaccine”, and “treatment”. We excluded case reports and some studies on the implementation of established techniques. Articles published before 1990 were also excluded, except when necessary. A total of 193 relevant articles were identified from the databases and included in this review.

**Drug-Resistance Mechanisms In *Shigella* Spp**

**Role Of Outer-Membrane Permeability**

Natural resistance to antimicrobial drugs by various mechanisms preventing the drug from being absorbed is capable of transforming the drug, its biotransformation into the cell, or reducing affinity with the drugs’ target. Cell walls of microorganisms are the first barrier against penetration of the drug. Some modifications of membrane permeability or changes in the membrane lead to porin loss, which can result in an increase in minimum inhibitory concentration (MIC) for antimicrobial agents. Most antibiotics used in treatment of *Shigella* infection should be able to penetrate the cell membrane to reach intracellular accumulation and target sites. For example, quinolone antibacterial agents, such as nalidixic acid, ofloxacin, and ciprofloxacin, interfere with DNA replication by inhibiting DNA topoisomerase IV and gyrase. Aminoglycoside antibiotics, such as streptomycin and spectinomycin, mediate inhibition of protein synthesis by binding to ribosomal subunits and reaching intracellular targets. β-Lactam antibiotics, eg, penicillin and cephalosporin, are a class of antibiotics containing a β-lactam ring in their molecular structures and inhibit cell-wall biosynthesis by targeting penicillin-binding proteins. Mutation or absence of ~39 kDa porin in the membrane of such Gram-negative bacteria as *Shigella* spp. mainly influences susceptibility to slow penetration of β-lactams, such as aztreonam and dianionic moxalactam, and also low permeability of hydrophilic antibiotics, such as penicillin and piperacillin. Indeed, resistance toward β-lactam antibiotics is associated with modification of the outer-membrane porins OmpF (~38 kDa) and OmpC (~42 kDa) and cytosolic proteins of ~26 kDa, OmpR as a transcriptional regulator. In a study, three imipenem-resistant mutants of *S. dysenteriae* were obtained from India and showed lower levels of both major OMPs (~38 and ~43 kDa). Increasing imipenem resistance in mutants was associated with permeability of outer-membrane proteins. Lipopolysaccharides (LPSs) have been recognized as an essential outer-membrane component needed for assembly of trimeric PhoE porin and confer colicin E2 resistance in *S. flexneri* strains and have also been reported to be linked with the rise in resistance toward imipenem in *S. dysenteriae*. Some outer-membrane components, such as IcsA molecules, are not only associated with bile salts resistance but are also related to promotion in development of biofilm by mediating bacterial cell–cell interactions. Consequently, they produce resistant phenotypes.

**Efflux Systems**

Active efflux pumps play a significant role in antibiotic-resistance phenotypes of Gram-negative bacteria and
expelling toxic compounds from their cells. Efflux systems are grouped into five families: the major facilitator superfamily (MFS), resistance–nodulation–division family, small multidrug resistance (MDR) family, ATP-binding cassette superfamily, and multidrug and toxic compound extrusion family. 17 AcrAB–ToIC pump is involved in antibiotic resistance phenotype of Escherichia spp., Enterobacter spp., Salmonella spp., and Shigella spp isolates. The AcrAB–ToIC system is a tripartite complex comprising ToIC (outer-membrane channel), AcrB (inner-membrane transporter protein), and periplasmic AcrA involved in assembly and maintenance of these two integral membrane proteins. AcrAB–ToIC belongs to resistance–nodulation–division family of efflux pumps, associated with efflux of quinolones, and one of factors responsible for development of resistance among Shigella isolates. Indeed, overexpression of AcrAB–ToIC results in overall decreased accumulation of quinolones inside bacterial cells, also resulting in reduced susceptibility to them. 18 AcrAB-associated to bile-salt resistance has been found in some strains of S. flexneri. Their expression has been shown to increase after exposure to bile salts, and enabled Shigella to resist bactericidal effects of bile. Researchers believe that this phenomenon may confer resistance to other antimicrobial agents. Furthermore, overexpression of AcrB has been found to be linked to multiple drug-resistance phenotypes in some Gram-negative bacteria. 19

Synergistic action regarding activation of acrAB–toIC efflux pumps has been shown to decrease expression of outer-membrane porins, gyrase, and topoisomerase target–gene mutations toward fluoroquinolone resistance in Shigella isolates. 20,21 Drug-efflux pumps, such as marA, tolC, ydhE, and mdfA, confer quinolone resistance. Kim et al demonstrated that resistance to fluoroquinolone is due to increased expression level of MdfA efflux pump in Shigella spp. This efflux is a member of the MFS antibiotic-efflux system, and MdfA efflux pump–mediated fluoroquinolone resistance was first identified among MDR Escherichia coli. 22 Tetracycline efflux and resistance is associated with the MFS antibiotic–efflux system encoded by various tet genes in Gram-negative bacteria, such as Shigella spp. and Klebsiella spp. Among tet efflux systems, it seems that tetA and tetB are mediated by resistance to tetracycline in S. sonnei and S. flexneri, respectively (for more details, refer to “Tetracycline Resistance” section). 11

Resistance To β-Lactam Antibiotics

Class A β-Lactamases

Class A β-lactamases can hydrolyze narrow-spectrum penicillin, but not carbapenems or cephalosporins, and are inhibited by tazobactam and clavulanic acid. Extended-spectrum β-lactamases (ESBLs) belong to Ambler class A. ESBLs conferring resistance to third-generation cephalosporins have been found in Shigella isolates. The first report documenting identification of ESBL-producing Shigella strains was from Bangladesh in 2004. 23 Emergence of ESBLs in Shigella spp is a global major health threat affecting both developed and developing countries. Different β-lactamases belonging to Ambler class A have been reported among Shigella isolates, such as TEM, SHV, and CTX-M enzymes. The first isolate of S. flexneri producing an ESBL and harboring a plasmid encoding the blaSHV-2 gene was reported from France in 1995. 24

To date, several reports from Argentina, Israel, Canada, Turkey, Lebanon, Japan, Iran, South Korea, China, and other various regions in Asia have identified Shigella spp harboring different types of ESBL genes (Table 1). 23,25–32 Although most ESBLs are derivatives of TEM and SHV β-lactamase families, which were first identified, Shigella spp can also express the CTX-M family, among which CTX-M-15 is one of the most relevant findings associated with the current epidemiology of ESBLs, which has been predominantly identified in commensal and pathogenic ESBL-producing Shigella isolates around the world. Despite many surveillance studies and investigations, the reason for this epidemiological shift remains unknown. 24,33 These enzymes are responsible for selective hydrolysis of ceftriaxone and cefotaxime and even more distinctly for ceftazidime, although some types of CTX-M, such as CTX-M-15, may hydrolyze ceftazidime. 33 In general, CTX-M-15 has been found to have great catalytic efficiency (high kcat/Km) against piperacillin, benzylpenicillin, ceftriaxone, and cefotaxime, as reported for other of CTX-M-types, such as CTX-M-3, CTX-M-16, and CTX-M-18.

To date, CTX-M-15 has been detected in Shigella isolates from various countries across the world, including Canada, Russia, Poland, the UK, France, Bulgaria, Turkey, and Iran. 34,35 CTX-M-type β-lactamases contain at least 40 enzymes, and these can be readily transferred among Shigella isolates by conjugative plasmids belonging to IncF, IncZ, and IncI groups. 34,35 Li et al revealed that ISEcp1 was present adjacently to all blaCTX-M genes in Shigella strains, meaning that it plays an important role in mobilizing blaCTX-M genes (Figure 1). 36 A large study conducted in Vietnam analyzed IncI1 plasmid pKHSB1 carrying blaCTX-M-15 collected from a clonal population of S. sonnei. 37 Another study reported full sequence of IncI1 plasmid pSH4469 carrying blaCTX-M-15 in a clinical isolate of S. sonnei isolated from an outbreak in South...
| Antimicrobial Class | Resistance Mechanism | Genes Mediating Antimicrobial Resistance | Origin | Geographic Origin | Reference |
|---------------------|----------------------|-----------------------------------------|--------|-------------------|-----------|
| β-Lactams           | Class A β-lactamases | β<sub>SHV</sub>-2                      | P      | Argentina, France | 32        |
|                     |                      | β<sub>SHV</sub>-11                     | C, P   | India             | 191       |
|                     |                      | β<sub>SHV</sub>-12                     | P      | China, Turkey     | 40        |
|                     |                      | β<sub>PER</sub>-2                     | —      | Argentina         | 32        |
|                     |                      | β<sub>TEM</sub>-1                     | I, P   | Lebanon, Chile, China, India, Iran, US, Djibouti, Denmark, France, Greece, Brazil, South Korea, UK, Romania | 25,26,31,40,120,192 |
|                     |                      | β<sub>TEM</sub>-1b                    | I, P   | China, South Korea | 34,40     |
|                     |                      | β<sub>TEM</sub>-15                    | –      | South Korea       | 28        |
|                     |                      | β<sub>TEM</sub>-17                    |        | South Korea       | 28        |
|                     |                      | β<sub>TEM</sub>-19                    | –      | South Korea       | 28        |
|                     |                      | β<sub>TEM</sub>-20                    | –      | South Korea       | 28        |
|                     |                      | β<sub>TEM</sub>-52                    | P      | South Korea       | 28        |
|                     |                      | β<sub>CTX-M</sub>-1                   | P      | China             | 40        |
|                     |                      | β<sub>CTX-M</sub>-2                   | P      | Argentina, Turkey, South Korea, Israel | 30,32,39 |
|                     |                      | β<sub>CTX-M</sub>-3                   | P      | China, Turkey, Argentina, South Korea, India, South Korea, Israel | 30,39,40 |
|                     |                      | β<sub>CTX-M</sub>-14                  | P      | China, Turkey, Argentina, South Korea, US, Japan | 39,40,193 |
|                     |                      | β<sub>CTX-M</sub>-15                  | C, P   | China, Spain, Iran, South Korea, India, US, Lebanon, Japan, Poland, New Zealand, France, Romania | 26,31,33,34,40,194 |
|                     |                      | β<sub>CTX-M</sub>-22                  | P      | China             | 51        |
|                     |                      | β<sub>CTX-M</sub>-24                  | P      | China             | 40        |
|                     |                      | β<sub>CTX-M</sub>-27                  | P      | China             | 40        |
|                     |                      | β<sub>CTX-M</sub>-28                  | –      | China             | 36,51     |
|                     |                      | β<sub>CTX-M</sub>-39                  | –      | Israel            | 30        |
|                     |                      | β<sub>CTX-M</sub>-55                  | P      | China, South Korea | 35,40     |
|                     |                      | β<sub>CTX-M</sub>-57                  | –      | China             | 51        |
|                     |                      | β<sub>CTX-M</sub>-64                  | P      | Japan             | 195       |
|                     |                      | β<sub>CTX-M</sub>-65                  | P      | China             | 192       |
|                     |                      | β<sub>CTX-M</sub>-79                  | P      | China             | 40        |
|                     |                      | β<sub>CTX-M</sub>-123                 | P      | China             | 40        |

(Continued)
| Antimicrobial Class | Resistance Mechanism | Genes Mediating Antimicrobial Resistance | Origin | Geographic Origin | Reference |
|---------------------|----------------------|----------------------------------------|--------|-------------------|-----------|
| **Class B β-lactamases** | bla<sub>IMP-1-like</sub> | P | India, France | 43, 46 |
|                     | bla<sub>KPC</sub> | – | Senegal, France | 46 |
|                     | bla<sub>IMP-3</sub> | P | Japan | 44 |
|                     | bla<sub>IMP-4-like</sub> | – | India | 43 |
| **Class C β-lactamases** | bla<sub>CMY-2</sub> | C, P | China, Mexico, India, Iran, Taiwan, Costa Rica, Romania | 48, 51 |
|                     | bla<sub>CMY-59</sub> | C | Iran | 31 |
|                     | bla<sub>DHA-1</sub> | C, I, P | China, India, Israel | 30, 51 |
| **Class D β-lactamases** | bla<sub>oxa-1-like</sub> | I, P | Mozambique, Chile, China, India, US, Egypt, Djibouti, Spain, Greece, Denmark, Peru, Iran | 105, 193, 196 |
|                     | bla<sub>oxa-2-like</sub> | I | Mozambique, Spain, Israel | 30, 105 |
|                     | bla<sub>oxa-5-like</sub> | – | Mozambique, Spain | 105 |
|                     | bla<sub>oxa-30-like</sub> | I, P | Senegal, China, France, Japan, Spain, Brazil | 51, 91, 120 |
| **Quinolones** | qnrA | P | Iran | 50, 75 |
|                     | qnrB | P | China, India, Iran | 64, 65, 75 |
|                     | qnrB4 | P | Switzerland | 61 |
|                     | qnrB<sub>19</sub> | P | Switzerland | 61 |
|                     | qnrC | P | India | 65 |
|                     | qnrS | P | Iran, China, India, Pakistan | 53, 64, 75, 94 |
|                     | qnrS<sub>1</sub> | P | Iran, China, Switzerland, US | 48, 61, 64 |
|                     | aac(-60)-Ib-cr | P | US, India, Japan, China, Iran | 50, 64, 66 |
| **Efflux pumps** | qepA | P | China, Switzerland | 61, 64 |
| **Fosfomycin** | fosA<sub>3</sub> | P | China | 38 |
| **Aminoglycosides: streptomycin** | strA | MGE | India, Australia, Chile, Pakistan, South Korea | 86, 93, 94, 97, 122 |
|                     | strB | MGE | India, Chile, Pakistan, South Korea | 86, 94, 97, 122 |
| **Adenytransferase** | aodA<sub>1</sub> | I, P | Senegal, Bhutan, India, Taiwan, Spain, China, Iran, France, Australia, Brazil, Pakistan, South Korea | 83, 86, 88, 91, 94, 97, 98, 120 |
|                     | aodA<sub>2</sub> | I, P | Taiwan, Spain, China, South Korea, France, Australia, Korea | 46, 83, 88, 97, 98 |
|                     | aodA<sub>5</sub> | I, P | Taiwan, China, Iran | 88, 98 |

(Continued)
Korea.\textsuperscript{34} The overall structure of plasmid pSH4469 was nearly identical to pKHSB1, and it seemed that both were responsible for dissemination of $\text{bla}_{\text{CTX-M-15}}$ among Shigella isolates (Figure 1).

| Antimicrobial Class | Resistance Mechanism | Genes Mediating Antimicrobial Resistance | Origin | Geographic Origin | Reference |
|---------------------|----------------------|-----------------------------------------|--------|------------------|-----------|
| Tetracycline        | Efflux pumps         | tetA                                    | C, P   | Mozambique, Taiwan, Chile, Peru, Brazil, Iran, Spain, Pakistan, South Korea | 11,88,94,97,104–106,120 |
|                     |                      | tetB                                    | C, P   | Mozambique, Taiwan, Peru, France, Brazil, Iran, Spain, Pakistan | 11,46,88,94,104,106,120 |
|                     |                      | tetG                                    | C, P   | Mozambique, Spain | 104,105 |
| Trimethoprim        | Dihydrofolate reductases | dfrA1 | I, P | Spain, Taiwan, Senegal, Mozambique, India, Bhutan, China, Iran, South Korea, Peru, France, Chile, Australia | 46,83,86,88,91,98,105,122 |
|                     |                      | dfrA5                                   | I, P   | Spain, Senegal, China | 91,98 |
|                     |                      | dfrA7                                   | I, P   | Spain, Iran, France | 46,106 |
|                     |                      | dfrA8                                   | P      | Mozambique, Chile | 105,122 |
|                     |                      | dfrA12                                  | I, P   | Spain, Taiwan, Korea, Australia, South Korea | 11,83,88,97 |
|                     |                      | dfrA13                                  | P      | South Korea | 97 |
|                     |                      | dfrA14                                  | P      | Mozambique, Chile | 105,122 |
|                     |                      | dfrA14-like                             | P      | Mozambique | 105 |
|                     |                      | dfrA15                                  | I, P   | Spain, Senegal | 91 |
|                     |                      | dfrA16                                  | P      | Spain | 91 |
|                     |                      | dfrA17                                  | I, P   | Taiwan, China, Iran, Brazil | 88,98,106,120 |
|                     |                      | dfrV                                    | I, P   | China, India | 98 |
| Sulfonamides        | Plasmid-borne resistance | sul1 | I, P | Australia, South Korea, Taiwan | 83,88,97 |
|                     |                      | Sul2                                    | I, P   | Taiwan, India, Peru, Chile, Bangladesh, South Korea | 86,88,97,122,126 |
|                     |                      | Sul3                                    | I, P   | Taiwan | 88 |
| Phenicols           | Chloramphenicol acetyltransferase genes | CatA-like | P | Taiwan, Mozambique, India, Peru, France, Brazil, Pakistan | 46,86,88,94,120 |
|                     | Efflux pumps         | cmlA1                                   | I, P   | Taiwan, Mozambique | 88,105 |
| Colistin            | Plasmid-borne resistance | mcr-1 | P | China, Vietnam | 112,116 |
| Macrolide           | Enzymatic inactivation | mpiA                                    | P      | Palestine, Switzerland, Vietnam, China, Canada, UK, Peru | 61,116,127,128,133 |
|                     | rRNA methylase       | emB                                     | P      | Vietnam, Canada, UK | 128,133 |

Abbreviations: P, plasmid; C, chromosome; I, integron; —, unknown; MGE, mobile genetic element.
Recently, a new hybrid of CTX-M-9 and CTX-M-1 β-lactamases named CTX-M-123 was identified among S. flexneri isolates from patients in China. In this study, bla\textsubscript{CTX-M-123} was carried by two conjugative plasmids named IncHI2 and IncF, and these conjugatable plasmids were responsible for dissemination of bla\textsubscript{CTX-M-123} in S. flexneri isolates.\textsuperscript{38} Moreover, several new β-lactamase subtypes — CTX-M-79, CTX-M-27, CTX-M-24, CTX-M-15, CTX-M-14, CTX-M-64, CTX-M-65, CTX-M-55, and CTX-M-3 — have been found in clinical Shigella strains isolated from different provinces in China.\textsuperscript{36,39,40} ESBL genes among Shigella isolates might be transferred from E. coli isolates to Shigella spp., especially S. sonnei isolates, through conjugation in human

---

**Figure 1** Schematic representation of bla\textsubscript{CTX-M-55}, bla\textsubscript{CTX-M-15}, and bla\textsubscript{TEM-1} genes in different types of plasmid. Arrows indicate positions and directions of different genes and IRL, terminal inverted repeats at the left; IRR, terminal inverted repeats at the right.

**Figure 2** Physical map of Shigella atypical class 1 integron and locations of bla\textsubscript{OXA-30} and aadA genes.
The increase in MDR and emergence of ESBL in *Shigella* spp. may be the cause of treatment failures and accordingly limitation in therapeutic options.\(^\text{41}\)

**Class B \(\beta\)-Lactamases**

Class B \(\beta\)-lactamase enzyme can hydrolyze carbapenem and other \(\beta\)-lactams, except for aztreonam, and classical \(\beta\)-lactamase inhibitors, such as tazobactam and clavulanic acid, do not inhibit them. Metallo-\(\beta\)-Lactamase was first detected in a transferable plasmid from *Pseudomonas aeruginosa*, and also IMP-1 was first identified from many kinds of Gram-negative rods in Japan.\(^\text{43,44}\) O’Hara et al reported a novel type of metallo-\(\beta\)-lactamase named MET-1 mediated by a *S. flexneri* plasmid. They believed that MET-1 was a derivative of IMP-1 \(\beta\)-lactamase.\(^\text{44}\) This plasmid conferred resistance against sulfonamide and kanamycin, in addition to \(\beta\)-lactamase.\(^\text{44}\) Lybe et al found that MET-1 experienced two amino-acid changes from IMP-1. The gene was renamed IMP-3, and thus IMP-3 could be considered an ancestor of IMP-1 \(\beta\)-lactamase. They also showed that this gene was located on a cassette inserted in a class I integron, widely disseminated among other species of *Shigella*, and conferred resistance to almost all \(\beta\)-lactam antibiotics.\(^\text{45}\)

Carbapenem resistance conferred by *bla*\(\text{VIM}\)* and *bla*\(\text{IMP}\)* genes has recently been detected in *S. sonnei* and *S. flexneri* isolates from pediatric patients with diarrhea in the Andaman and Nicobar islands in India.\(^\text{43}\) In this study, after analysis of nucleotide sequencing of *bla*\(\text{IMP}\)* and *bla*\(\text{VIM}\)* genes by BLAST, 100% similarity with sequences of these genes isolated from *Acinetobacter baumannii* and *P. aeruginosa* available at the NCBI database was confirmed. After spread of carbapenem resistance to *Shigella* in another part of the world, an indication of a potential public health challenge, treatment options will be limited, and infection-control measures remain of high importance.\(^\text{43}\) Finally, although class A \(\beta\)-lactamase KPC is one of the most commonly identified carbapenemases among other Gram-negative bacteria in some parts of the world, it has not yet been identified in *Shigella* isolates, except for a single *bla*\(\text{KPC}\)*-carrying *S. flexneri* strain isolated from the National Senegalese Enterobacteriaceae Center located at the Pasteur Institute in Dakar.\(^\text{46}\)

**Class C \(\beta\)-Lactamases**

Ceftriaxone is recommended for treatment of ciprofloxacin-resistant *Shigella* isolates. However, today some strains of *Shigella* spp. have a resistance gene to cephalosporins. Class C \(\beta\)-lactamases, also known as AmpC-type enzymes, confer high-level resistance against cephalosporins. AmpC \(\beta\)-lactamase is encoded by both plasmid and chromosomal genes, and the first report of plasmid-encoded CMY-2-type AmpC \(\beta\)-lactamase was detected among ceftriaxone-resistant *S. sonnei* isolates obtained from an outbreak of bacillary dysentery in Taiwan.\(^\text{47}\) CMY-2 enzymes have been reported in China, Taiwan, Costa Rica, Iran, and India from several epidemic strains.\(^\text{47-50}\) Zhang et al found two AmpC \(\beta\)-lactamase producers with *bla*\(\text{CMY-2}\)* and *bla*\(\text{DHA-1}\)* in *Shigella* strains recovered from diarrhea patients in China.\(^\text{51}\)

Tajbakhsh et al reported on the first AmpC \(\beta\)-lactamase (*bla*\(\text{CMY-2}\)*) producers in *S. sonnei* isolated from patients in Tehran, Iran.\(^\text{46}\) In recent years, other studies conducted in Iran have indicated spread of resistance to extended-spectrum cephalosporins among *Shigella* isolates.\(^\text{31,50}\) In a similar study carried out in Iran, studying cephalosporin-resistant *Shigella* isolates, the researchers identified gene CMY-59 in one *S. sonnei* isolate from pediatric patients aged <12 years.\(^\text{31}\) However, the majority of AmpC-positive isolates studied in other parts of the world belonging to the CMY-2 genotype and other AmpC genes (*bla*\(\text{MOX}\), *bla*\(\text{FOX}\), *bla*\(\text{MIRA}\)\(\text{CT-1}\), *bla*\(\text{CIT}\), and *bla*\(\text{ACC}\)) have been identified in *Shigella* isolates; however, so far there has not a study on them.\(^\text{52,53}\) Indeed, few reports have described the presence of AmpC \(\beta\)-lactamases among *Shigella* isolates worldwide (see Table 1 for more details).\(^\text{47,48}\)

**Class D \(\beta\)-Lactamases**

Class D \(\beta\)-lactamases or OXA-type \(\beta\)-lactamases confer resistance to ampicillin and cephalothin and can hydrolyze oxacillin and cloxacillin, as well as benzylpenicillin, but they are not inhibited by tazobactam or other inhibitors.\(^\text{52,54}\) Initially, *bla*\(\text{OXA}\)* \(\beta\)-lactamases were reported among *P. aeruginosa* isolates, although now *bla*\(\text{OXA}\)* genes have been identified in integrons and plasmids in many Gram-negative bacteria.\(^\text{55}\) In *Shigella* spp., resistance to ampicillin is mainly associated with an OXA-type \(\beta\)-lactamase.\(^\text{54,56}\) *bla*\(\text{OXA-30}\)* was initially described in ampicillin-resistant *S. flexneri* strains from China in 2000.\(^\text{57}\) Results of some studies have shown that *S. flexneri* isolates are a probable host specific for *bla*\(\text{OXA-30}\)-type \(\beta\)-lactamase.\(^\text{52,58}\) Another study from Iran showed that all *bla*\(\text{OXA-30}\)*-positive isolates carried *bla*\(\text{OXA-1}\)* and many of them were present in *S. flexneri*, suggesting an individual host preference of these enzymes in *S. flexneri* isolates.\(^\text{50}\)

*bla*\(\text{OXA-1}\)* and *bla*\(\text{OXA-30}\)* genes, containing Tn2603 and Tn1409 transposons, respectively, differ from each other by having one mutation at codon 131. A gene encoding *bla*\(\text{OXA-1}\) \(\beta\)-lactamases is carried on integron.\(^\text{58}\) Furthermore,
other studies have shown that blaOXA-30 and aadA1 are located in the gene cassettes of class 1 integrons (Figure 2). Therefore, class 1 integrons carry resistance traits for β-lactams (blaOXA) and trimethoprim (dfrA1). Data presented in Table 2 show that mutation patterns in gyrA and parC genes, particularly common mutations, are similar to those reported by other studies, reflecting a universal pattern among Shigella spp. A direct contribution to quinolone and fluoroquinolone resistance by each of these mutations in chromosomal target–site mutations (QRDRs) remains unknown. However, other mechanisms may be present in Shigella isolates, and further investigations are needed.

Quinoline and Fluoroquinolone Resistance
Resistance To (Fluoro)quinolones Due To Chromosomal Target–Site Mutations
Corresponding subunits for DNA gyrase and topoisomerase IV are gyrA, gyrB, parC, and parE, encoded by genes gyrA, gyrB, parC, and parE genes, respectively. DNA gyrase consists of two gyrA subunits and two gyrB subunits, and topoisomerase IV contains two parC and two parE subunits. The most mutations have been found in a small region near the start of the gyrA gene termed a quinolone resistance–determining region (QRDR), between Ala67 and Gln107, and as reported in several studies (Table 2), most frequently mutations occur at codons 83, 87, and 211, while mutations in gyrB were detected with lower frequencies in different studies. Some researchers believe that when a single mutation occurs in gyrA, it may confer resistance to quinolones, but for decreased susceptibility to fluoroquinolones, a number of further mutations in parC and gyrA regions are needed. parC gene mutations most frequently occur at codons 80 among Shigella isolates. gyrA gene mutations have been confirmed to be much more prevalent than mutations in the gyrB gene. Most nucleotide and amino-acid changes in QRDRs of gyrA, gyrB, parC, and parE among Shigella spp. are shown in Table 2. Novel mutations in QRDRs have also been identified from different regions of the world. Two novel mutations at codons 86 and 129 in parC and a mutation in codon 211 of gyrA were first reported in S. sonnei strains recovered from China in 2009.

Finally, two novel mutations at codons 408 and 458 in parE have recently been discovered among Shigellaspp., isolated in India in 2013 and Jiangsu Province in China in 2016. Mutation in codon 458 is believed to result in resistance to ciprofloxacin and nalidixic acid, while a single isolate with a mutation at codon 408 in parE is related to resistance to nalidixic acid, but susceptible to ciprofloxacin. It seems that both the novel mutations in parE of S. flexneri isolates may be correlated with the increased MIC for ciprofloxacin and mediate fluoroquinolone resistance. Also, in neither study were parE mutations identified among quinolone-sensitive isolates.

In the US, the Shigella resistance rate to fluoroquinolones reached 87% during 2014–2015. Resistance of Shigella isolates to fluoroquinolone is mainly due to mutational alterations in QRDRs of DNA gyrase and topoisomerase IV genes, but PMQRs may facilitate in selection of isolates exhibiting higher levels of resistance through extrachromosomally encoded mechanisms and confer reduced susceptibility to quinolones (or fluoroquinolones). aac(6′)-Ib-cr and qnrS genes were first identified in isolates of S. flexneri 2a in 1998 and S. flexneri serotype 1a in 2002, respectively. Furthermore, the qnrS gene was identified in isolates of Shigella flexneri 2b in 2005 in Japan. Also, as reported in two previous studies, aac(6′)-Ib-cr and qnrS were predominant PMQR determinants across two provinces in China, conferring high levels of fluoroquinolone resistance. These studies indicated that aac(6′)-Ib-cr–positive Shigella isolates have been present in China for many years.
Table 2: Frequency of Amino-Acid and Nucleotide Changes in the Quinolone Resistance-Determining Regions of Shigella Isolates in Different Parts of the World

| Target Site Mutations | Codon | Amino-Acid Changes | Nucleotide Mutation | Shigella spp. | Country of Detection | Reference(s) |
|-----------------------|-------|--------------------|---------------------|---------------|----------------------|--------------|
| 57 Asn→Lys | GyrA | AAT→AAA | S. flexneri | China | 197 |
| 69 Gln→Trp | S. sonnei | India | 65 |
| 71 Phe→Ser | S. sonnei | India | 65 |
| 72 Ser→Pro | S. sonnei | India | 65 |
| 75 Met→Leu | S. sonnei | India | 65 |
| 80 His→Pro | CAT→CCT | S. flexneri | China | 197 |
| 80 His→Gly | CAT→GGT | S. dysenteriae | Belgium | 197 |
| 83 Ser→Leu | TCG→TTG | S. sonnei, S. flexneri, S. dysenteriae, S. boydii | China, Bangladesh, Switzerland, Thailand, India | 21,58,61,64 |
| 87 Asp→Asn | GAC→AAC | S. sonnei, S. flexneri, S. dysenteriae | China, Bangladesh, Switzerland, India | 21,52,64 |
| 87 Asp→Gly | GAC→GGC | S. sonnei, S. flexneri, S. dysenteriae | China, Switzerland, Thailand, India | 21,61,64 |
| 87 Asp→Tyr | GAC→TAC | S. sonnei, S. flexneri | Switzerland | 61 |
| 90 Ser→Cys | S. sonnei | India | 65 |
| 94 Met→Leu | S. sonnei | India | 65 |
| 106 His→Pro | S. sonnei | India | 65 |
| 116 Asn→His | S. sonnei | India | 65 |
| 116 Thr→Ala | S. sonnei | India | 65 |
| 116 Val→Ala | S. flexneri, S. dysenteriae | India | 21 |
| 211 His→Tyr | CAC→TAC | S. sonnei, S. flexneri | China, Bangladesh | 8,62,64 |
| 517 Gln→Arg | GyrB | CAG→CGA | S. flexneri | China | 62,71 |
| 64 Ala→Asp | GCC→GAC | S. sonnei, S. flexneri | India, China | 65 |
| 64 Ala→Cys | GCC→TGC | S. sonnei | China | 65 |
| 80 Ser→Ile | AGC→ATC | S. sonnei, S. flexneri, S. dysenteriae | China, Bangladesh, Switzerland, India | 21,40,57,61,62,64 |
| 81 Ala→Pho | — | S. flexneri | China | 71 |
| 83 Ser→Leu | — | S. flexneri | China | 30 |
| 85 Ser→Thr | S. flexneri | China | 71 |
| 85 Ala→Ser | GGC→TCG | S. boydii | Switzerland | 61 |
| 86 Met→Thr | ATG→TGG | S. sonnei | China | 64 |
| 91 Gln→His | — | S. flexneri | China | 71 |
| 93 Phe→Val | — | S. flexneri, S. dysenteriae | India | 21 |
| 101 Asp→Glu | — | S. flexneri, S. dysenteriae | India | 21 |

(Continued)
Indeed, streptomycin resistance is qnrS strains to harbor novel enzymes activated through the years. Importantly, qnrS-positive isolates of Shigella, especially S. flexneri strains, show high-level resistance to fluoroquinolones, and many researchers from different parts of the world suggest that the plasmid-mediated quinolone-resistance gene qnrS plays an essential role in reduced susceptibility of Shigella strains to fluoroquinolones. Indeed, qnrS plasmid could change fluoroquinolone susceptibility of S. flexneri isolates containing both gyrA83 and parC80 mutations into ciprofloxacin-resistant isolates. Overall, aac(6’)-Ib-cr is the most prevalent gene, followed by qnrS detected in isolates of S. flexneri from the US, India, Japan, China, and Iran, and also most studies have highlighted an increased prevalence of PMQR determinants through the years. A recent study conducted in China reported that aac(6’)-Ib-cr-positive isolates and qepA-positive isolates expressed high levels of quinolone resistance. This finding indicates that other mechanisms, such as reduced outer-membrane permeability, active efflux pumps, and harboring of different resistance genes, may be responsible for resistance to quinolones.

### Fosfomycin Resistance

Fosfomycin (Fom) is a broad-spectrum antibiotic inhibiting bacterial cell-wall biogenesis by inactivating the MurA enzyme. Despite the use of Fom in treatment of microbial infections for four decades, Fom has remained effective against common uropathogens, and Fom resistance has remained rare throughout the world. However, Fom resistance was observed among E. coli strains to harbor novel transferable fosfomycin-resistance determinants named FosC2 and FosA3. Two primary resistance mechanisms have been described for fosfomycin resistance: mutations in uhpA/T and glpT genes encoding proteins for two carrier-dependent systems responsible for fosfomycin uptake, and attainment of fosfomycin-modifying enzymes containing two kinases, FomA and FomB, and three types of metalloenzymes: FosX, FosA, and FosB.

Fosfomycin-modifying enzymes were discovered for the first time among S. flexneri strains isolated from patients in China. Some studies have suggested that increasing prevalence of fosA3 was due to dissemination of IncN and IncI plasmids, facilitating its quick dispersal. Indeed, ESBL (blaCTX-M-123, blaCTX-M-55, or blaCTX-M-15) and fosA3 genes were cored by transconjugant plasmids from diverse incompatibility groups, and all of them contained determinants encoding resistance to cefotaxime, ceftriaxone, and fosfomycin. In this regard, conjugatable plasmids are likely to play an essential role in dissemination of fosA3 and ESBL genes among Shigella isolates with high clonal diversity, and they should be closely monitored.

### Aminoglycoside Resistance

Aminoglycosides are used to treat a wide range of infections. Aminoglycosides mediate inhibition of protein synthesis. Resistance to aminoglycosides is associated with enzymatic inactivation, ribosomal modification, and active efflux pumps. Among these mechanisms, aminoglycoside-modifying enzymes are the most common in the clinical setting. These enzymes are activated through three general reactions, resulting in adenylation, acetylation, or phosphorylation. Aminoglycoside adenylyltransferase (aadA gene cassettes) are very common in Enterobacteriaceae, especially among Salmonella and Shigella isolates, conferring resistance to streptomycin and spectinomycin. Indeed, streptomycin resistance is

---

**Table 2 (Continued).**

| Target Site Mutations | Codon | Amino-Acid Changes | Nucleotide Mutation | Shigella spp. | Country Of Detection | Reference(s) |
|-----------------------|-------|--------------------|---------------------|--------------|---------------------|--------------|
| 110                   | Asp→Glu | —                 | —                   | S. flexneri, S. dysenteriae | India     | 21             |
| 111                   | Asp→His | GAT→CAT           | S. flexneri         | China        | 62,64              |
| 129                   | Ser→Pro | TCC→CCC           | S. sonnei           | China        | 62,64              |
| **parE**              | 408    | Gly→Asp           | GGC→GAC            | S. flexneri  | China              | 62             |
| 458                   | Ser→Leu | TCG→TTG           | S. sonnei, S. flexneri, S. dysenteriae | China, India | 62             |
| 458                   | Ser→Ala | TCG→GCG           | S. sonnei, S. flexneri, S. dysenteriae | India       | 62             |

**Note:** —, unknown.
strongly associated with integrons because of the high prevalence of aadA gene cassettes within class 1 and 2 integrons. A typical class 2 integron has a gene cassette of 2.2 kb with a resistance-gene arrangement (dfrA1–sat–aadA1) conferring resistance to trimethoprim, streptomycin, and spectinomycin/streptomycin, respectively, while aadA1 was absent in atypical class 2 integrons.87,88 Class 2 integrons have been identified in transposon Tn7 and predominantly inserted into chromosomes with high frequency.89 An atypical class 1 integron with an unusual 3’ conserved sequence carrying an estX-psp-aadA2-cmlA-aadA1–qacH cassette array has been detected among different Gram-negative species (E. coli, Shigella, and Salmonella) from different hosts (human, animal, and food), periods and geographical regions. Accordingly, horizontal transfer of these integrons by plasmids promotes spread of multiple-resistance genes in sporadic and outbreak isolates of Shigella.89–91

Many types of aadA gene cassettes have been identified among Enterobacteriaceae, but types aadA1 and aadA2 have high prevalence among Shigella isolates.84,89,92 Aminoglycoside phosphotransferases encoded by strA and strB are the most common genes dispersed among Shigella isolates by plasmids, such as IncFII and pNV-Y394.85,87,93,94 The gene encoding strA has been identified in 42.1% of Shigella isolates recovered from diarrheal patients in Pakistan.95 In a study conducted in India, 100% and 88% of S. dysenteriae type 1 and S. sonnei strains harbored strA genes, encoding resistance to streptomycin.96 The majority of Shigella isolates harbored strA and strB, along with unrelated resistance determinants, which are coded by blaTEM, blaCTX-M, qnrS, aadA1, tet(A), tet(B), catA, and catT.95,96 A 6.3 kb plasmid has been detected in the S. flexneri 3a strain and is involved in a streptomycin-resistance phenotype. This plasmid is likely to cause acquired resistance to streptomycin.97 Also, a study conducted in South Korea showed that resistance to streptomycin was mediated by strA or strB among S. sonnei isolates obtained there and revealed that tetA, strA–strB, and sul1 were encoded and present in 8.4 kb of untransferable R plasmid.98

Occurrence of aminoglycoside-resistance genes among Shigella isolates does not occur, because these drugs have long been excluded for treatment of shigellosis in different geographical areas.85 However, there is still a concern, because class 1 integrons containing the gene-cassette array of blaOXA-30 + aadA1 with complete 3’CS have been reported on plasmids in Shigella spp. isolates, Salmonella enterica serovar Typhimurium and E. coli strains, and transferable plasmids may enhance spread of resistance genes within integrin, establishing arols of plasmids in horizontal transfer of resistance genes.99

### Tetracycline Resistance

Tetracyclines are used against a wide variety of diseases in humans and animals.100 Tetracycline-resistant bacteria are found in opportunistic pathogens and normal flora species. According to the study by Roberts101 and nomenclature for tetracycline resistance genes(https://faculty.washington.edu/marilynn), five tetracycline-efflux genes — tet(A), tet(B), tet(C), tet(D), and tet(G) — and one ribosomal protection protein encoded by tet(M) have been identified among Shigella isolates, most of which are encoded in transmissible elements, with extensive dissemination in different groups of bacteria. In a study, a 20.4 kb genomic island was identified encoding MDR genes, such as a wide variety of tet genes flanked by transposas.102 This identical MDR cassette was first identified in S. flexneri serotype 2a strain YSH6000 and was referred to as Shigella resistance locus–pathogenicity island.103 Interestingly, these MDR genes have recently been found in an E. coli plasmid, pRSB225, with a similar arrangement.104 The IncB/O/K/Z-type plasmid, termed p866, carrying resistance genes tet(A) and tet(B) have been identified in S. sonnei strains.105 These findings suggest that tet genes might be dispersed among other species by horizontal gene transfer.

Among 154 tetracycline-resistant isolates recovered as confirmed causes of traveler’s diarrhea in Spain, 79.2% (n=122) harbored at least tet(A) or tet(B). Combinations of tet(A) + tet(B), tet(A) + tet(G), and tet(B) + tet(G) were found in one, one, and seven isolates, respectively.106 Results of two studies revealed that tet(A) was more frequent among S. sonnei strains, whereas tet(B) was more frequent among S. flexneri strains.106,107 Also, S. sonnei and S. flexneri differed from each other in terms of prevalence of plasmid Inc groups.106 In 50 isolates of Shigella spp. identified from stool samples collected from children with diarrhea in Iran, 90% and 18% of isolates carried tetA and tetB, respectively, and no positive results were identified for tet(C) or tet(D) in this study.11 Results of the same study conducted in Iran revealed that tet(A) and tet(B) were present in 75.7% and 21.42% of Shigella spp. and that tet(A) was more frequent in S. flexneri and S. sonnei populations.108

A study carried out in Mexico identified genes tet(A), tet(B), and tet(C) in 1, 6, and 18 S. sonnei isolates, and 2,
7, and 1 S. flexneri isolates, respectively, whereas tet(D) was observed only in S. sonnei isolates (8%). Among 20 S. dysenteriae isolates from dysentery outbreaks obtained from different parts of India, tet(B) was more common (90%) than tet(A) (10%). In the same study, genes tet(A) and tet(B) were detected in 15% and 79% of Shigella isolates, respectively, samples of which were obtained from children with diarrhea in southern Mozambique. Based on recent studies, it seems that efflux-mediated tetracycline resistance to tetracycline in S. sonnei and S. flexneri strains may be related to expression of tet(A) and tet(B), respectively. According to tetracycline resistance–gene nomenclature (https://faculty.washington.edu/marilynry), tet(B) is able to confer resistance to minocycline, while other efflux pumps encoded in a transferable tet gene do not have such a property and may cause clonal dissemination of tet(B)-positive Shigella isolates worldwide. In general, tet(A) and tet(B) are the most prevalent tetracycline-resistance genes in Shigella spp. Other tetracycline-efflux genes, such as tet(C) or tet(D), are rarely detected alone.

**Phenicol Resistance**

Phenicols have used to treat Shigella infections during the past few years around the world, and application of them led to strong selective pressure for resistance to these antibiotics. Resistance in Shigella is associated with enzymatic inactivation of unfluorinated phenicols by chloramphenicol acetyltransferase genes encoded by variants of catA (catA1, catA2, catA3) and catB (catB2, catB3, catB7, catB8), as well as active efflux by cmlA (cmlA1, cmlA4, cmlA9) and/or fluorinated and unfluorinated phenicols (floR) by major facilitator–superfamily proteins. Chloramphenicol resistance in Shigella isolates is mainly associated with the presence of cat genes. Among 95 Shigella isolates collected from diarrheal patients in Pakistan, at least 69 (72.6%) were resistant to chloramphenicol. catA and catP were detected in 32 (33.68%) and 24 (25.26%) isolates, respectively, from chloramphenicol-resistant Shigella isolates. Among 103 S. sonnei isolates associated with several waterborne outbreaks in Taiwan, in 84% of sporadic isolates, tetB and catA genes were transferred along with 130 kb plasmids. The presence of catA encoding chloramphenicol O-acetyltransferase was detected and confirmed in S. flexneri strains with strA or aadA1 genes or both.

**Colistin Resistance**

Colistin (polymyxin E) is a polypeptide antimicrobial agent interacting with outer membranes of Gram-negative bacteria. Since the first report of the plasmid-mediated polymyxin-resistance gene mcr-1 was published in an E. coli isolate in November 2016 in China, this gene has also been identified in Salmonella enterica and Klebsiella pneumoniae, but is rarely reported in other Enterobacteriaceae members here. This gene has now been identified in other Enterobacteriaceae genera, such as Shigella, Cronobacter, Klyvera, and Enterobacter isolated from vegetables, the environment, food, animals, and human beings. The mechanism of resistance of mcr-1 is produced by a phosphotidylethanolamine transferase, leading to modification of lipid A present as a result of addition of phosphoethanolamine to lipid A in cell membranes of Gram-negative bacteria, resulting in more cationic LPSs and lower affinity for colistin and related polymyxins and consequently reduced antimicrobial activity. The presence of mcr-1 in Shigella isolates leads to a four- to eightfold increase in the MIC of polymyxin B. mcr-1 is located on various plasmid backbones, including IncI2, IncFIl, IncFI2, IncFIB, IncP, IncY, and IncX4, sized 58–252 kb (Figure 3). ESBL-encoding genes or other resistance genes might coexist with it. Also, plasmid-mediated colistin-resistant S. flexneri isolates recovered from animal feces on a farm showed that it might be circulated via the fecal–oral route, at least between animals on that farm, and possibly distributed via the food-production network. In most reports, mcr-1 is known to be the only resistance gene for related plasmids, indicating that selective pressure associated with polymyxin is responsible for mcr-1 acquisition. It means that other plasmids conferring MDR phenotypes can be achieved from resistant S. flexneri strains. Mobile elements, such as IS and integrons, could also help isolates acquiring other resistance elements from the environment. A novel transposon, Tn6390 has been detected in S. flexneri C960, in which two copies of ISApl1 bracketed to the mcr-1 gene play a pivotal role in transposition of mcr-1. Recently, mcr-1 was identified in S. sonnei isolates from Shanghai (2010–2012) with polymyxin B resistance (MIC 4–8 μg/mL).

**Sulfonamide And Trimethoprim Resistance**

After the spread of trimethoprim–sulfonamide resistance in different parts of the world, these agents are currently considered ineffective for empirical therapy of shigellosis. Acquired resistance mechanisms have frequently been
identified, mostly due to mutational or recombinational changes in target enzymes (dihydropteroate synthase and dihydrofolate reductase, respectively) or acquired resistance by drug-resistant target enzymes, such as acquired sul genes coding for drug-resistant dihydropteroate synthases or dfr genes coding for drug-resistant dihydrofolate reductases.120,121

Resistance To Trimethoprim
At least 42 dfr genes conferring trimethoprim resistance have been detected in different groups of bacteria worldwide, 12 of which have been identified in Shigella spp. Resistance to trimethoprim might be explained by the presence of integron-borne dfr genes (Figure 4). Gene cassettes within class 1 integrons detected on plasmids or chromosomes in Shigella isolates often encode resistance to trimethoprim (dfrA), streptomycin (aadA), and ampicillin (oxa-1).58,85 Class 2 integrons borne on Tn7 have often been found in Shigella spp., and gene-cassette arrays of them usually contain dfrA1, sat1, and aadA1.122

The presence of dfrA1 genes among Shigella isolates is the main mechanism of trimethoprim resistance, occurring in a cassette in both class 1 and class 2 integrons (Figure 4). Two types of class 2 integrons among S. sonnei strains have been identified in Japan. One of them was typical type of class 2 integrons (2,158 bp) with dfrA1, sat1, and aadA1 cassette arrays, and the other was an atypical type of class 2 integrons (1,313 bp) carried only two gene-cassette arrays with dfrA1 and sat1.123 This integron-associated antibiotic resistance can be transferred to other species via plasmid conjugation. dfr12–orfF–aadA2, dfr17–aadA5, and aadA1 cassette arrays carried by class 1 integrons have been recognized in S. sonnei isolates recovered from South Korea, China, Vietnam, and Australia.84,85,99 Also, dfrA1–sat1–aadA1–orfX, free aadA1, or free orfX cassette arrays carried by class 2 integrons have been detected in Senegalese Shigella spp. isolates.92 In contrast to dfrA genes, dfrB genes have not been identified among Shigella isolates. Recently, trimethoprim-resistance clones were sequenced.
by primer walking, and a native 6,779 bp plasmid was identified with presence of the \textit{dfrA14} gene in a \textit{sul2}--\textit{strA}--\textit{dfrA14}--\textit{strA}--\textit{strB} gene arrangement in \textit{S. sonnei} strains, suggesting that \textit{dfrA14} was associated with a small nonconjugative plasmid.\textsuperscript{124} Class 2 integrons within a \textit{dfr1}--\textit{sat2}--\textit{aadA1} cassette array were predominant in \textit{S. sonnei} isolates from outbreaks cases in Taiwan, while class 2 integrons were absent in sporadic cases.\textsuperscript{89} A large study conducted in South Korea analyzed 122 \textit{S. sonnei} isolates collected from stool samples in different parts of the country from 1991 to 2000. Resistance to trimethoprim was associated with \textit{dfrA1} and \textit{dfrA12}. \textit{dfrA1} was found as a gene cassette of Tn7 located in chromosomes, while \textit{dfrA12} was located in conjugative R plasmids as a gene cassette of class 1 integrons. Tn7 was not detected in \textit{S. sonnei} isolates recovered from the 1980s, while in this study Tn7 was found in all \textit{S. sonnei} isolates. The authors proposed that \textit{S. sonnei} isolates carrying Tn7 were responsible for outbreaks of shigellosis in different parts of South Korea in the 2000s.\textsuperscript{98}

**Resistance To Sulfonamides**

Since the first report of resistance to sulfonamides was found in both \textit{S. sonnei} and \textit{S. flexneri} isolates recovered from the early 1970s in South Korea,\textsuperscript{98,125} resistance to this antibiotic has been identified in 94% of \textit{S. sonnei} strains.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure4.png}
\caption{Variable regions of class 1 (A) and class 2 (B) integrons reported in different geographic area. Horizontal arrows indicate transcriptional orientation of genes.}
\end{figure}
from the 1980s and 100% of isolates from the 2000s and 2010s in different parts of the world.\textsuperscript{2,50,118} Sulfonamide resistance is mediated by \textit{sul1}, \textit{sul2}, and \textit{sul3} genes, and they are common in \textit{Shigella}.\textsuperscript{89} The \textit{sul1} gene is highly frequent among \textit{Shigella} isolates, because it is part of the 3′-conserved sequence region of class 1 integrons. Also, \textit{sul3}, linked to an unusual 3′-conserved segment, is associated with class 1 integrons.\textsuperscript{89,126} According to one study, \textit{sul2} is one of the three sulfonamide-resistance genes, and is usually located on large transmissible plasmids or small non-conjugative plasmids and was first detected on a small nonconjugative plasmid of \textit{E. coli}.\textsuperscript{90} Since then, this gene has been found mostly on plasmids in \textit{Shigella} isolates from humans in South Korea,\textsuperscript{98} Taiwan,\textsuperscript{99} Australia,\textsuperscript{127} and Bangladesh.\textsuperscript{128}

Several studies have suggested that \textit{sul} genes are linked to other resistance genes. The \textit{sul1} gene is often identified together with other antimicrobial-resistance genes located on gene-cassette arrays in variable regions of class 1 integrons. Class 1 integrons differ from class 2 in their excise gene cassettes, capacity to integrate, and presence of \textit{sul1} in 3′ conserved region (3′CS). In Brazil, \textit{sul1} (sulfonamide-resistant) was identified in two (3%) MDR \textit{Shigella} samples, which were also positive for class 1 integrons.\textsuperscript{122} In previous studies on MDR \textit{S. sonnei} isolates obtained in South Korea, resistance to sulfamethoxazole was mainly associated with \textit{sul1}, located in 8.4 kb of nonconjugative R plasmid.\textsuperscript{98}

Antibiotic-resistance gene clusters containing \textit{strA}, \textit{strB}, and \textit{sul2} are widespread among Gram-negative bacteria, particularly in \textit{Shigella} isolates.\textsuperscript{124} Iqbal et al\textsuperscript{128} found \textit{sul1}, \textit{sul2}, \textit{sul3}, integron 1, and integron 2 genes in all MDR \textit{S. flexneri} 2a strains, and also found that \textit{sul2} was absent in all sulfamethoxazole-sensitive strains (n=54), while it was present in all sulfamethoxazole-resistant strains (n=146). However, in this study, no change was observed in expressions of \textit{sul1}, \textit{sul3}, integron 1, or integron 2 genes in sulfamethoxazole-resistant and -sensitive \textit{S. flexneri} 2a strains. Interestingly, curing of this 4.3 MDa plasmid resulted in loss of \textit{sul2} and susceptibility to sulfamethoxazole in paired strains, suggesting involvement of \textit{sul2} and this plasmid in resistance to sulfamethoxazole. In the same study, 24 \textit{S. sonnei} isolates were detected to carry an atypical class 1 integron associated with \textit{sul3}. The \textit{estX–psp–aadA2–cmlA1–aadA1–qacH} cassette array of \textit{sul3}-associated class 1 integron has been found to encode an esterase, a lipase, putative phosphoserine phosphatase/resistance to streptomycin, chloramphenicol, and quaternary amines.\textsuperscript{23}

**Macrolide Resistance**

The American Academy of Pediatrics and the Infectious Diseases Society of America have recommended azithromycin as a medication for treatment of shigellosis in children, and also the WHO introduced it as second-line treatment in adults.\textsuperscript{129} The Centers for Disease Control and Prevention has observed resistance to azithromycin in approximately 3% of \textit{Shigella} cases tested. Resistant outbreaks involving \textit{Shigella} spp. isolates with reduced susceptibility to azithromycin (RSA) are more recent phenomena and continually detected in Asia, North America, the US, Australia\textsuperscript{130,131} and other geographic regions.\textsuperscript{132–134} According to updated Clinical and Laboratory Standards Institute guidelines, if MIC measured by broth microdilution is \(\leq 16\) and \(\leq 8\ \mu g/mL\), then epidemiological cutoff values denote susceptibility for \textit{S. sonnei} and \textit{S. flexneri} wild-type, and if MIC is \(\geq 32\) and \(\geq 16\ \mu g/mL\), then susceptibility is confirmed for non–wild-type, respectively.\textsuperscript{135} Recently, several reports have suggested that resistance to azithromycin in \textit{Shigella} spp. isolates is associated with presence of \textit{mphA} or \textit{ermB} plasmid-mediated genes or by both genes.\textsuperscript{133,136} Macrolide resistance is mediated by four main mechanisms: enzymatic inactivation by phosphotransferases encoded by \textit{mph} genes or esterases encoded by \textit{ere} determinants; target-site modification by an rRNA methylase encoded by \textit{erm} genes; punctual mutations in \textit{rplV} encoding L22 ribosomal protein, \textit{rplD} encoding L4 ribosomal protein, and \textit{rrlH} (23S rRNA); and drug-resistance mediated by efflux pumps, such as OmpA, OmpW, mefA, and msrA.\textsuperscript{137,138} All macrolide-resistance mechanisms can mediate resistance to azithromycin and erythromycin. The \textit{mphA} gene was first identified in an \textit{E. coli} isolate from Japan.\textsuperscript{139} Since then, this gene has been recognized among \textit{Pseudomonas} spp., \textit{Aeromonas} spp., \textit{Stenotrophomonas} spp., \textit{Shigella} spp., and other enteropathogens.\textsuperscript{137} Dissemination and acquisition of macrolide \textit{mphA} resistance mechanisms in \textit{Shigella} spp. has been shown to be mainly due to spread of plasmids from \textit{E. coli}.\textsuperscript{140} All the discovered \textit{mphA}-associated plasmids have been identified in \textit{E. coli} isolates, indicating their role as a repository from which antimicrobial resistance to \textit{Shigella} spp. may appear.\textsuperscript{135} This phenomenon has been previously described in \textit{E. coli} donating \textit{mphA} to \textit{S. sonnei}.\textsuperscript{141}

Additionally, \textit{Shigella} strains with RSA have been found mostly in strains recovered from men who have sex with men (MSM; 68.8% or higher) from the Montreal region. In this study, complete sequence analysis of six selected plasmids from different serotypes of \textit{S.}}
flexneri and S. sonnei emphasized the role of IS26 in dispersal of RSA. Also, in a study conducted in Taiwan, a series of clonally related azithromycin-insusceptible Shigella spp. isolates was reported in relation to MSM. Various gene-transfer systems (mobile genetic element acquisitions) are involved in acquiring antibiotic-resistance genes, such as transposons, integrons, and conjugative plasmids. The IS26–mpfa–mrx–mphR (A)–IS6100 gene cassette has been characterized in a clinical strain of S. boydii carrying the p2246–CTXM plasmid. Insertion sequences of IS6100 and IS26 have been found in the neighborhood of mpfa in an S. sonnei strain recovered from France. Indeed, in addition to plasmid mobilization, dissemination, and acquisition of RSA among Shigella spp. and serotypes has also potentially occurred through IS26 mobilization.

IncFI and IncFII plasmids have been shown to carry the azithromycin-resistance gene erm. The IncFI plasmid containing an ISCR3 insertion sequence surrounds both ermC and ermB genes and carries a blaCTX-M-24 gene downstream of an ISECpl element. The IncFII plasmid carries ermB and ermC genes downstream of an IS6 transposase. Both plasmids share significant DNA homology with other previously sequenced plasmids found in S. sonnei and S. flexneri serotype 3a isolates associated with development of the disease in MSM.

Recently, a plasmid carrying azithromycin-resistance genes, namely pKSR100 (conjugative R-plasmid) in S. flexneri serotype 3a has been described to be involved in intercontinental spread of RSA among DSM-associated outbreak lineage. pKSR100-like plasmids have been found to be predominantly related to DSM-associated outbreak lineage in Australia and elsewhere. There are a considerable number of studies on the prevalence of RSA among Shigella isolates throughout the world, particularly in MSM, and demonstrated global dissemination of a multi-resistant plasmid, highly associated with MSM, which is present across different continents.

Biofilm Formation–Mediated Resistance

Recently, much attention has been given to biofilm formation in bacteria, because microbial cells grown in biofilms are less sensitive to antimicrobial agents and more resistant to environmental stress such as dehydration and oxidation. Microbial infections caused by biofilm-associated Shigella spp. are global health challenges. Biofilm formation is regulated by a multifactorial process, with cellular adherence, exopolysaccharide secretion, and numerous gene regulations controlling detachment of bacteria from mature biofilm, and is mainly related to quorum sensing and social networking in the microbial world. Ellafi et al investigated biofilm formation by Shigella strains grown in different NaCl concentrations, and they showed that all the isolates produced biofilm. According to their study, biofilm formation is a protective system under different environmental stress conditions. Recent studies have demonstrated that bile salts increase the capacity of S. flexneri strains to adhere to and penetrate epithelial cells. Indeed, extended exposure of Shigella to bile salts occurred in cases of increased biofilm formation, and thus it is an important resistance mechanism for Shigella sp. Similar biofilm phenotypes have been observed for Campylobacter, Listeria, and Vibrio, demonstrating that bile salt–induced biofilm production is conserved among members of the Enterobacteriaceae family. Also, biofilm formation has been shown to require the presence of glucose, whereas biofilm diffusion requires the elimination of bile salts from the medium. Bacteria in the form of biofilm can be 100,000 times more resistant to antimicrobial agents than planktonic forms of bacteria in the same species. During biofilm formation, the effect of shf, mdoH, VpsT, and LuxR-like genes and OpgH protein expression has been confirmed among enteric bacteria, as well as Shigella. Another study described biofilm-formation potentials and pathological behaviors of various mutants S. flexneri strains with an incomplete inner core of LPS containing only Kdo moieties.

Interestingly, 1rafC (also called waac) mutant, with an incomplete inner core of LPS due to deficiency in Hep biosynthesis, shows strong biofilm-formation ability and considerably high invasiveness and adhesiveness to human epithelial cells compared LPS-mutant strains. However, this strategy is successful in conferring high-level resistance only in bacterial species with a deficiency in Hep synthesis of LPS. The relationship between biofilm formation and pathogenicity, as well as virulence factors and antimicrobial properties, has not been thoroughly studied in Shigella spp., and further studies are needed.

Therapeutics

Treatment for Shigella infections is recommended to prevent spread of infection to others and to shorten disease duration. According to current WHO guidelines and a systematic review, the use of fluoroquinolones (first-line,
preferably ciprofloxacin), cephalosporins (second-line), and β-lactams (second-line) for 7–10 days is recommended for treatment of shigellosis. In regions known to have high rates of resistance to ciprofloxacin, azithromycin may be considered appropriate second-line therapy. Cefixime is also a good alternative, although its use should be balanced with respect to risk of developing antimicrobial resistance and spread of ESBL. Conventional antibiotic therapeutics against shigellosis have become increasingly inefficient, due to the increase in number of MDR strains. However, no well-designed in vitro or in vivo combinations of anti-microbial agents have been performed to evaluate different antibiotic-class regimens for treating infections caused by Shigella. There has only been a related study on an anti-microbial-sensitivity case series reporting resistance in different regions and treatment outcomes for infections caused by Shigella. In general, it has been observed that there is a decrease in susceptibility to first- and second-line agents. As such, there is an urgent need for development of novel therapeutic strategies for treatment of MDR Shigella infections.

**Alternative Therapeutics**

**Natural And Organic Products**

Natural products are small molecules produced naturally by microbial agents, plants, and animals that have been demonstrated to be useful in treating Shigella infections. Biotherapeutic agents (preferably probiotics) have been suggested in prevention of antibiotic-induced diarrhea, and are also an alternative therapeutic choice for treatment of gastroenteritis infectious. Bacteria and yeast are the most frequent microorganisms used as probiotics. Several mechanisms have been suggested for antimicrobial activity of bacteria toward enteric bacterial pathogens, including production of undissociated organic acids, organic acid molecules, and bacteriocin, competition for adhesion sites, and coaggregation with pathogens.

Pretreatment of cells with bacterial components and products obtained from *Lactobacillus rhamnosus* and *L. acidophilus* results in interference with Shigella adherence and internalization into host cells and leads to an absence of IL8 expression, substantiating attenuation of inflammatory response during aggregate pretreatment. Lactobacilli have been shown to regulate cytokine production and stimulate the immune system. Time-kill methodology has shown that viability of *S. sonnei* decreased after contact with cell-free culture supernatants of lactobacilli, which could be potentially used as probiotic strains in food industry.

Zhang et al selected a total of 91 lactobacilli for antimicrobial activity against Shigella isolates, among which 16 lactobacilli displayed potent antibacterial activity against *S. sonnei* strains. The nature of these antimicrobial agents was studied and found to be dependent on production of organic acids. Also, other studies have indicated that lactobacilli and lactic and acetic acid bacteria possess high activity against MDR Shigella pathogenic strains, and that they can be the best candidate for probiotics. *Saccharomyces boulardii* is a thermophilic and nonpathogenic yeast showing antagonistic activity against several bacterial pathogens, such as enterohemorrhagic and enteropathogenic *Escherichia coli*, *Vibrio cholera*, *Salmonella typhimurium*, and *S. flexneri*.

In one study, the effect of aqueous ethanol extract of *Euphorbia prostrata* was investigated in vitro and in vivo on bacterial growth of *S. dysenteriae* type 1 and found to be effective against Shigella isolates, with MIC and minimal bactericidal concentration of 3,500–12,000 µg/mL. The preventive role of orally administered *Aloe barbadensis* Miller (*Aloe vera*)—supplemented probiotic lassi (APL) was determined for *S. dysenteriae* infection in mice, with a significant (*P<0.05*) decrease found in Shigella counts (log CFU/mL) and immunoprotective effects of APL against *S. dysenteriae*. Antivirulence activity of a boiling black tea (*Camellia sinensis*) extract was shown to reduce expression of virulence traits by *S. dysenteriae*, as shown by decreased bacterium-survival strategies, and also an enhancement was found in innate immunoresponse against Shigella isolates. Antishigellosis activity of *Pieralima nitida* Stapf (Apocynaceae) extract has been found to be effective against *S. dysenteriae* type I strains, and MIC and minimal bactericidal concentration were 800 and 6,400 µg/mL, respectively. In vitro antibacterial activity of methyl gallate isolated from *Terminalia chebula* has been shown to cause total disintegration of outer and inner membranes and leakage of cytoplasmic contents of MDR *S. dysenteriae*. Viable intracellular *S. dysenteriae* reduced in a time-dependent manner in the presence of methyl gallate and decreased to zero within 20 hours. In another study, antimicrobial activity of thyme oil and ciprofloxacin and their synergistic effects were evaluated, and the combination displayed differing degrees of effects on microbial cell formation based on results obtained from scanning electron microscopy and transmission electron microscopy. In vitro and in vivo synergy between them showed maximum growth inhibition in *S. flexneri*. 

**In vivo and in vitro**
Bacterial loads in infected colons reduced as a result of treatment with thyme oil, while the conventional drug failed to heal colon ulcers. Also, it decreased penetration of lamina propria by inflammatory cells.¹⁶²

Antishigellosis activity of a Crinum jagus water-ethanol extract was found to be effective against S. flexneri, with inhibition of diameter by 18.90 (0.39 mg/mL) and 25.36 (200 mg/mL) mm, respectively. Indeed, Crinum jagus extract drastically decreased (P<0.01) diarrheal stool emission and microbial load and also reduced IFNγ, IL2, IgM, IgA, and motilin blood levels in S. flexneri-induced diarrheic rats.¹⁶³ An in vitro study on bovine lactoferrin recognized it as a coadministered adjuvant therapeutic in antibiotic therapy against Shigella isolates. Some strains of Shigella show a twofold or more decrease in their ampicillin MIC values in the presence of bovine lactoferrin.¹⁶⁴ In vitro data showed that antibacterial activity of gallic acid inhibited the effect on biofilm formation and reduced the number of viable S. flexneri strains. Indeed, gallic acid inhibited biofilm formation in S. flexneri by regulating expression of the mdoH gene. mdoH is essential for glucosyltransferase activity and osmoregulated periplasmic glucans synthesis, as they both contribute to biofilm formation and develop antibiotic resistance in pathogenesis. Inhibition of mdoH can help in treatment of S. flexneri biofilm.¹⁴³ Organic acids, such as citric, acetic, lactic, and malic acid, are natural substances categorized as “generally recognized as safe” according to the US Food and Drug Administration. They have antimicrobial activity and are widely used to inactivate bacteria. Results of a study showed that organic acids, carvacrol, and their combination were useful against S. sonnei. However, S. sonnei was shown to decrease to 4.53 and 3.25 log CFU/mL using 0.5% w:v malic, lactic acid, respectively, indicating the synergistic effect of combination therapy.¹⁶⁵ A previous study reported the effects of dithiocarbamate transition-metal complexes on survival and recovery of pathogenic bacteria, and they are very attractive and novel pharmaceutical targets for control and management of antibiotic-resistant bacteria, as well as Shigella isolates.¹⁶⁶

Novel Therapeutic Strategies For Shigella Treatment

Nanoparticles

Nanoparticles (NPs) have gained growing importance in recent years and shown broad-spectrum antibacterial activity against pathogenic bacteria, due to their bactericidal characteristics.¹⁶⁷ NPs usually destroy bacterial targets with a damaging effect on membrane load cells and their integrity, along with generation of free oxygen radicals. Commonly, they can be delivered efficiently as antimicrobial agents. Recently, copper oxide NPs have been recognized as an antimicrobial agent for treatment of Shigella. MIC and minimum bactericidal concentration of copper oxide NPs were 2,500 μg/mL and ≤5,000 IU/mL, respectively, in treatment of S. sonnei using 33 nm NPs. The study also showed that smaller copper oxide NPs had stronger antibacterial effects than larger NPs at a specific time and concentration.¹⁶⁸ Iron is a biocompatible element, and can be directly used for treatment of many types of microbial pathogens. In one study, antimicrobial properties of Fe₂O₃ and Ag–Fe₂O₃ NPs against S. dysenteriae strains was evaluated, and both Fe₂O₃ and Ag–Fe₂O₃ NPs were shown to have antimicrobial effects, with antimicrobial activity of Ag–Fe₂O₃ NPs much more than that of Fe₂O₃ NPs alone.¹⁶⁹ The bactericidal effect of iron oxide NPs has been determined, with values of 50–100 μg/mL against Gram-positive and Gram-negative bacteria, as well as S. dysenteriae and E. coli.¹⁶⁷ The use of nanoantibiotic formulations is another strategy for treatment of drug-resistant Shigella. Mukherjee et al reported on the synthesis of a nanosized form of tetracycline by loading it in calcium phosphate NPs and showed that this treatment significantly decreased incidence of colon-length shortening, mushy-stool excretion, weight loss, and microbial colonization in gastrointestinal tracts of Shigella-infected mice. Immunohistological research has shown that as a result of tetracycline–calcium phosphate NP treatment, changes in morphology and level of inflammatory cytokines IL1β, IFNγ, and TNFα in intestinal tissue of mice caused by shigellosis were reverted to almost normal characteristics.¹⁷⁰ Silver NPs (AgNPs) are characterized by their broad-spectrum bactericidal toxic effects against broad-spectrum bacterial pathogens. Omara et al tested AgNPs against pathogenic Salmonella and Shigella strains recovered from layer-poultry farms. AgNPs at a concentration of 16 μg/mL were found to have both bacteriostatic and bactericidal effects against Salmonella and Shigella isolates.¹⁷¹ Although NPs have shown high antibacterial activity during in -vitro and in -vivo experiments, future studies and judiciously performed clinical trials are required to achieve a better understanding of their potential side effects and clear regulatory guidelines.
Phage Therapy

Bacteriophages (phages) are the most abundant organisms killing bacteria through lysis mechanisms. They can be recovered from various environments. Phage therapy has earned increasing attention due to several advantages, including high specificity to target bacteria without effects on normal microflora of the human body, replication at infection site, bactericidal activity against antibiotic-resistant bacteria, and fewer side effects than other therapies. Phages are self-limiting, because phages remain at a shallow level on target sites after killing bacterial targets. Phage therapy of shigellosis was discovered by a French microbiologist named d’Herelle, who described efficacy of phages in curing symptoms of dysentery. Use of phages for treatment of MDR S. dysenteriae recovered from wastewater has been investigated as an alternative to antibiotics. Another study showed that a virulent phage named pSb1 was able to infect all the S. boydii strains and had productive lytic activity against them. Also, results indicated that pSb1 might be a member of an N4-like phage group and might have potential applications as an alternative option for treatment of shigellosis. Regular targeting of only a subgroup of strains within one bacterial species or closely related species without causing distortions in the gut microbiota is one of the benefits of phage treatment over antibiotic therapy in treatment of shigellosis. Numerous animal have studies demonstrated that phages are able to survive in experimental animals with dysentery. Despite no reports on significant undesirable reactions during the long history of phage therapy in humans, phage treatments still need to overcome admission constraints in the main medical repertoire.

Vaccine Strategies

Varieties of candidate vaccines have been developed to prevent infection by Shigella spp., most of which are currently under evaluation for safety and immunogenicity. However, there is no licensed vaccine available against this pathogen. At present, studies in humans and animals have shown that protection by vaccination is possible. Potential candidates for Shigella vaccines include glycoconjugate vaccines, such as recombinant glycoconjugate, synthetic glycoconjugate, O-polysaccharide covalently linked to immunogenic carrier proteins, virG-based live attenuated (WRSS1, WRSs3, WRSf3, WRSf2G12, WRSf2G15 and WRSd1), recombinant outer-membrane proteins, live attenuated vaccines, invasion-plasmid antigens B, C, and D, DNA-based vaccines, Ty21a typhoid vaccine expressing Shigella LPS, recombinant probiotic-based candidates, and whole-cell-killed and Shigella trivalent inactivated whole-cell and heat-killed multiserotype Shigella, as well as novel antigen candidates, such as triacylated S-LPS, subcellular complexes purified from virulent cultures (Invaplex), GMMA protein particles, and an OMV-NP vaccine (Table 3). Live attenuated strains such as S. dysenteriae type 1 WRSd1, S. sonnei WRSS1, WRSs2, WRSs3, and some whole-cell-killed and novel antigen candidates are now developing, and were safe and immunogenic in a phase I trial (more details are presented in Table 3). Among possible Shigella candidate vaccines, GMMA protein particles, live attenuated Shigella flexneri 2a SC602, and S. dysenteriae type 1 SC599 strains have entered phase II clinical evaluation, and only glycoconjugate candidates have already undergone Phase III trials, with other formulations still under development in patients with shigellosis. As shown in Table 3, many studies have demonstrated humoral response as a main value of an immunoresponse to vaccination, and also fever and transient diarrhea have been reported as the most frequent complications in relation to some vaccine candidates in clinical investigations (Table 3). Finally, it seems that development and evaluation of multivalent candidates may provide a means for protection against serogroups/serotypes of Shigella in future.

Conclusion

In this review, antibiotic-resistance mechanisms and therapeutic strategies have been summarized regarding Shigella infection. Antimicrobial resistance in Shigella spp. is multifactorial in that it can occur through innate, acquired, or adaptive mechanisms, and infections resulting from it are exceedingly difficult to treat. Drug resistance among Shigella spp. occurs as a result of selective pressure and horizontal resistance-gene transmission. Accordingly, there is an urgent need to comprehensively learn and understand mechanisms of drug resistance among Shigella isolates, in order to develop antishigellosis drugs. The multifarious nature of antibiotic-resistance mechanisms contributes in an increase in the number of MDR strains and causes conventional antibiotic therapeutics to be highly inefficient against shigellosis. Despite intensive research efforts in the last few decades related to determination of antimicrobial resistance, researchers have not been able to find the best solution to control MDR isolates. Also, direct contributions to antibiotic resistance by many antimicrobial-resistant mechanisms remains unknown, showing a need for continuous monitoring of a broader range of associated mechanisms contributing...
| Class/type                  | Investigational Vaccines | Delivery Systems | Target Antigen (Type) | Valued Immunoresponse | Status And Results                          | Limitations                              | Development Phase | Reference |
|----------------------------|--------------------------|------------------|-----------------------|-----------------------|--------------------------------------------|------------------------------------------|--------------------|-----------|
| Live vaccine               |                          |                  |                       |                       |                                            |                                          |                    |           |
| Live-vaccine candidate strain | *Escherichia alberti* strain DM104 | Intransal          | Whole-cell *E. alberti* | Humoral               | Completed, efficacy, protection in guinea pigs | Unknown                      | Preclinical       | 198       |
| Attenuated vaccines        |                          |                  |                       |                       |                                            |                                          |                    |           |
| Live attenuated strains    |                          |                  |                       |                       |                                            |                                          |                    |           |
| *S. flexneri* 2a WRSf2G12, WRSf2G15 |                          | Ocular           | *virG, set, senA, sbB2* genes | Humoral               | Ongoing, protection in guinea pigs          | Needs balancing immunogenicity with reactogenicity | Preclinical       | 176       |
| *S. dysenteriae* type I    |                          | Oral             | *virG* gene           | Humoral               | Efficacy when given orally                  | Transient diarrhea                | Phase I            | 199       |
| *S. flexneri* 2a (SC602)   |                          | Oral             | *virG, iuc* genes     | Humoral               | Completed, efficacy, protection             | ND                          | Phase IIB         | 200       |
| *S. dysenteriae* type I    |                          | Oral             | *virG, ent, fep, stbA* genes | Humoral               | Completed, efficacy, protection             | Unknown                       | Phase II           | 201       |
| *S. sonnei* WRSS1          |                          | Oral             | *virG* gene           | Humoral               | Ongoing, need for human challenge models for the efficacy of the vaccine | Fever, transient diarrhea          | Phase I            | 174       |
| *S. sonnei* WRSs2, WRSs3   |                          | Oral             | *virG, senA, senB, mbB2* genes | Humoral               | Ongoing, prevention in guinea pigs and needs further development | Unknown                       | Preclinical       | 179       |
| *S. flexneri* 2a CVD 12085 |                          | Oral             | guoB* A gene         | Humoral               | Completed, efficacy, prevention and induces diverse T-CMI responses in human volunteers | ND                          | Phase II           | 180       |
| RNA-binding protein mutants of *S. dysenteriae* type I and *S. sonnei*  |                          | Oral and Ocular  | *hfg* gene and ipoBCDA plasmid | Humoral               | Ongoing, induced protective immunity       | Animals vaccinated in the eye showed fewer symptoms | Preclinical       | 181       |

(Continued)
| Class/type                        | Investigational Vaccines                                                                 | Delivery Systems | Target Antigen (Type)                  | Valued Immunoresponse | Status And Results                                                                 | Limitations                        | Development Phase | Reference |
|----------------------------------|-----------------------------------------------------------------------------------------|------------------|----------------------------------------|-----------------------|-----------------------------------------------------------------------------------|-----------------------------------|-------------------|-----------|
| Hybrid and live attenuated vectors | *Salmonella enterica* serovar Typhi strain, Ty21a                                         | Oral             | O-antigen biosynthesis gene            | Humoral               | Completed, efficacy, protection in mice                                            | Unknown                          | Preclinical       | 182       |
|                                  | *S. flexneri* 2a                                                                         | Oral and oral    | virG, oroA genes                       | Humoral               | Ongoing, efficacy and future investigation need for more attenuated recombinant mutant strains | Fever and diarrhea                | Phase II         | 202       |
| Live transconjunctive *Shigella* hybrid (LT9HΔstx) strain | Oral                                                                                     | Oral             | stx gene                               | Humoral and cellular  | Completed, efficacy and good protection in mice                                   | Unknown                          | Preclinical       | 203       |
| *Escherichia coli* K12           |                                                                                         | Oral             | pWR10–R64rdII invasiveness plasmid     | Humoral               | Stopped, causes mild diarrhea in human primates                                    | Fever, mild diarrhea to frank dysentery | Preclinical       | 204       |
| *E. coli* K12, EcSf2a-3, EcSf2a-5 |                                                                                         | Oral             | virG, oroD genes                       | Humoral               | Stopped, EcSf2a was immunogenic but also reactogenic and thus not sufficiently attenuated in the guinea pig | Not sufficiently attenuated       | Preclinical       | 204       |

**Inactivated vaccines**

| Whole cell–killed vaccines       | *Shigella* with a truncated O-SP                                                          | Intranasal       | wzy gene                               | Humoral               | Completed, efficacy, protection                                                    | ND                                | Preclinical       | 205       |
|                                  | *S. flexneri* 2a                                                                         | Oral             | Inactivated whole cells                | Humoral and cellular  | Completed, safety, robust immunoresponse                                            | ND                                | Phase I          | 204       |
|                                  | *S. sonnei*                                                                              | Oral             | Inactivated whole cells               | Humoral               | Completed, efficacy, protection                                                    | ND                                | Phase I          | 205       |
|                                  | Trivalent of *Shigella* whole cells                                                      | Intranasal       | Formalin inactivation of *S. flexneri* 2a, *S. sonnei*, and *S. flexneri* 3a | Humoral               | Completed, efficacy, protection from lethality in guinea pig infection model        | Unknown                          | Preclinical       | 184       |
|                                  | Heat-killed multiple serogroups/serotypes of *Shigella* (HKMS)                           | Oral             | *S. dysenteriae* 1, *S. flexneri* 2a, *S. flexneri* 3a, *S. flexneri* 6, *S. boydii* 4 and *S. sonnei* | Humoral and cellular  | Completed, efficacy, protection in rabbit infection model                           | ND                                | Preclinical       | 185       |
Table 3 (Continued).

| Class/type | Investigational Vaccine | Delivery Systems | Target Antigen (Type) | Valued Immunoresponse | Status And Results | Limitations | Development Phase | Reference |
|------------|-------------------------|------------------|-----------------------|-----------------------|-------------------|------------|-------------------|-----------|
| Subunit vaccines | IpaDB fusion proteins | Intradermal | Invasion plasmid antigens B and D (IpaB and IpaD) | Humoral | Ongoing, protective efficacy using a mouse pulmonary infection model | ND | Preclinical | 178 |
| | rIpaB domain rGroEL | Lung | S. flexneri IpaB, S. Typhi GroEL | Humoral | Immunogenic and protective efficacy against S. flexneri, S. boydii and S. sonnei in BALB/c mouse infection model | ND | Preclinical | 207 |
| Glycoconjugate candidates | Bioglycoconjugates | Intramuscular | S. dysenteriae 1 LPS exoprotein A | Humoral | Ongoing, protection, additional serotypes will be tested shortly | ND | Phase I | 208 |
| | Lipid-linked S. dysenteriae–type 1 O-polysaccharide | Intramuscular | O-SP Ag | Humoral | Ongoing, need future studies using synthetic saccharides of different size | Low level of antibodies | Preclinical | 209 |
| | O-polysaccharide covalently linked to immunogenic carrier proteins | Subcutaneous | O-SP Ag | Humoral | Ongoing studies | Unknown | Preclinical | 174 |
| | Synthetic oligosaccharides | Intramuscular | S. flexneri 2a O-SP Ag tetanus toxoid | Humoral | Ongoing, need future studies for the development of multivalent glycoconjugate vaccines | Unknown | Preclinical | 209 |
| Novel antigen candidates | Artificial Invaplex (recombinant IpaB and IpaC proteins with purified Shigella LPS) | Intranasal | LPS, IpaB, and IpaC Ag | Humoral | Efficacy, protection in mice, need future tests for determination of safety and immune response in humans | ND | Preclinical | 186 |
| | Triacylated S-LPS | Parenteral | Partial alkaline deacylation of S-LPS | Humoral | Completed, efficacy, protection with robust humoral immunoresponse | Unknown | Phase I | 108 |
| | GMMA protein particles | - | Outer-membrane particles from S. sonnei and S. flexneri 2a | Humoral | Completed, good safety and immunogenicity profiles in healthy adults | ND | Phase Ila | 187 |
| | ΔtolA-OMV vaccine | Intramuscular | Outer-membrane vesicles, disruption of tolA gene from S. boydii 4 | Humoral | An ongoing, potentially cost-effective vaccine in the mouse infection model | ND | Preclinical | 210 |
| | OMV-nanoparticle vaccine | Intranasal | Shigello outer-membrane vesicles | Humoral | Ongoing, need future studies for the development of a multivalent vaccine | ND | Preclinical | 188 |
to development of MDR strains. Most candidate vaccines cause an improvement in host immunity along with prevention of infection, but some have low efficiency and host challenge, which must be thoroughly overcome before being used against Shigella infection. More understanding on the host–microbe relationship is needed to develop novel therapeutic strategies to fight shigellosis. Development of innovative therapeutic and alternative strategies is also required for prevention and treatment of Shigella infections.

**Author Contributions**

Both authors conceptualized and designed the review, contributed towards data analysis, drafting and critically revising the paper, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Kahsay AG, Muthupandian S. A review on sero diversity and antimicrobial resistance patterns of Shigella species in Africa, Asia and South America, 2001–2014. *BMC Res Notes*. 2016;9 (1):422. doi:10.1186/s13104-016-2236-7

2. Puzari M, Sharma M, Chetia P. Emergence of antibiotic resistant Shigella species: a matter of concern. *J Infect Public Health*. 2018;11(4):451–454. doi:10.1016/j.jiph.2017.09.025

3. Qu F, Bao C, Chen S, et al. Genotypes and antimicrobial profiles of Shigella sonnei isolates from diarrheal patients circulating in Beijing between 2002 and 2007. *Diagn Microbiol Infect Dis*. 2012;74(2):166–170. doi:10.1016/j.diagmicrobio.2012.06.026

4. Organization WH. *Antimicrobial Resistance: Global Report on Surveillance*. World Health Organization; 2014.

5. Grimont F, Lejay-Collin M, Talukder KA, et al. Identification of a group of shigella-like isolates as Shigella boydii 20. *J Med Microbiol*. 2007;56(6):749–754. doi:10.1099/jmm.0.46818-0

6. Raja SB, Murali MR, Devaraj SN. Differential expression of ompC and ompF in multidrug-resistant Shigella dysenteriae and Shigella flexneri by aqueous extract of Aegle marmelos, altering its susceptibility toward beta-lactam antibiotics. *Diagn Microbiol Infect Dis*. 2008;61(3):321–328. doi:10.1016/j.diagmicrobio.2008.02.006

7. Taneja N, Mewara A. Shigellosis: epidemiology in India. *Indian J Med Res*. 2016;143(5):565–576. doi:10.4103/0971-5916.187104

8. Qu S, Wang Y, Xu X, et al. Multidrug-resistant atypical variants of Shigella flexneri in China. *Emerg Infect Dis*. 2013;19(7):1147. doi:10.3201/eid1909.130682

9. Traa BS, Walker CLF, Munos M, Black RE. Antibiotics for the treatment of dysentery in children. *Int J Epidemiol*. 2010;39 (suppl 1):i70–i84. doi:10.1093/ije/dyp024

10. Bhattacharya D, Bhattacharya H, Thamizhmani R, et al. Shigellosis in Bay of Bengal Islands, India: clinical and seasonal patterns, surveillance of antibiotic susceptibility patterns, and molecular characterization of multidrug-resistant Shigella strains isolated during a 6-year period from 2006 to 2011. *Eur J Clin Microbiol Infect Dis*. 2014;33(2):157–170. doi:10.1007/s10096-013-1937-2

11. Shahsavani S, Owlia P, Lari AR, Bakhshi B, Nobakht M. Investigation of efflux-mediated tetracycline resistance in Shigella isolates using the inhibitor and real time polymerase chain reaction method. *Iran J Pathol.* 2017;12(1):53.
12. Poole K. Outer membranes and efflux: the path to multidrug resistance in gram-negative bacteria. Curr Pharm Biotechnol. 2002;3(2):77–98. doi:10.2174/138920102378454 

13. Kar AK, Ghosh AS, Chauhan K, et al. Involvement of a 43-kilodalton outer membrane protein in beta-lactam resistance of Shigella dysenteriae. Antimicrob Agents Chemother. 1997;41(10):2302–2304. 

14. Ghosh AS, Kar AK, Kundu M. Impaired imipenem uptake associated with alterations in outer membrane proteins and lipopolysaccharides in imipenem-resistant Shigella dysenteriae. J Antimicrob Chemother. 1999;43(2):195–201. doi:10.1093/jac/d43.2.195 

15. Tran EN, Papadopoulos M, Morona R. Relationship between O-antigen chain length and resistance to colicin E2 in Shigella flexneri. Microbiology. 2014;160(Pt 3):589–601. doi:10.1099/mic.0.074955-0 

16. Koseoglu VK, Hall CP, Rodriguez-Lopez EM, Agaisse H. The autotransporter IcsA promotes Shigella flexneri biofilm formation in presence of bile salts. Infect Immun. 2019. doi:10.1128/iai.00861-18 

17. Sun J, Deng Z, Yan A. Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations. Biochem Biophys Res Commun. 2014;453(2):254–267. doi:10.1016/j.bbrc.2014.05.090 

18. Yang H, Duan G, Zhu J, et al. The AcrAB-ToIC pump is involved in multidrug resistance in clinical Shigella flexneri isolates. Microb Drug Resist. 2008;14(4):245–249. doi:10.1089/mdr.2008.0847 

19. Nickerson KP, Chanin RB, Sistrunk JR, et al. Analysis of Shigella flexneri resistance, biofilm formation, and transcriptional profile in response to bile salts. Infect Immun. 2017;85(6). doi:10.1128/iai.01667-16 

20. Kim FY, Kim SH, Jeon SM, Park MS, Rhie HG, Lee BK. Resistance to fluoroquinolones by the combination of target site mutations and enhanced expression of genes for efflux pumps in Shigella flexneri and Shigella sonnei strains isolated in Korea. Clin Microbiol Infect. 2008;14(8):760–765. doi:10.1111/j.1469-0691.2008.02033.x 

21. Taneja N, Mishra A, Kumar A, Verma G, Sharma M. Enhanced resistance to fluoroquinolones in laboratory-grown mutants & clinical isolates of Shigella due to synergism between efflux pump expression & mutations in quinolone resistance determining region. Indian J Med Res. 2015;141(1):81–89. 

22. Edgar R, Bibi E. MdiA, an Escherichia coli multidrug resistance protein with an extraordinarily broad spectrum of drug recognition. J Bacteriol. 1997;179(7):2274–2280. doi:10.1128/jb.179.7.2274-2280.1997 

23. Rahman M, Shoma S, Rashid H, Siddique AK, Nair GB, Sack DA. Extended-spectrum beta-lactamase-mediated third-generation cephalosporin resistance in Shigella isolates in Bangladesh. J Antimicrob Chemother. 2004;54(4):846–847. doi:10.1093/jac/dkh413 

24. Fortineau N, Naas T, Gailleot O, Nordmann P. SHV-type extended-spectrum beta-lactamase in a Shigella flexneri clinical isolate. J Antimicrob Chemother. 2001;47(5):685–688. doi:10.1093/jac/dgj5.685 

25. Matar GM, Jaafar R, Sabra A, et al. First detection and sequence analysis of the bla-CTX-M-15 gene in lebanese isolates of Escherichia coli from patients with bacillary dysentery in Lebanon. J Infect Dev Ctries. 2010;4(5):283–287. doi:10.1016/j.jidc.2010.04.009 

26. Rashid H, Rahman M. Possible transfer of plasmid mediated extended-spectrum beta-lactamase resistance between Escherichia coli and Shigella sonnei in the human gut. Infect Genet Evol. 2015;30:15–18. doi:10.1016/j.meegid.2014.11.023 

27. Liu Y, Deng Z, Yan A. Characterization of extended-spectrum beta-lactamase genes of Shigella flexneri isolates with fosfomycin resistance from patients in China. Ann Lab Med. 2017;37(5):415–419. doi:10.3343/alm.2017.37.5.415 

28. Zhang R, Zhou HW, Cai JC, et al. Serotypes and extended-spectrum beta-lactamase types of Shigella isolates from the Zhejiang province of China. Diagn Microbiol Infect Dis. 2011;69(1):98–104. doi:10.1016/j.diagmicrobio.2010.08.027 

29. Liu G, Qian H, Tang B, et al. Prevalence and characterisation of third-generation cephalosporin-resistant Shigella flexneri isolates from Jiangsu Province, China, 2013–2015. J Glob Antimicrob Resist. 2018;15:283–287. doi:10.1016/j.jgar.2018.08.012 

30. Ranjbar R, Ghazi FM, Farshad S, et al. The occurrence of extended-spectrum beta-lactamase producing Shigella spp. in Tehran, Iran. Iran J Microbiol. 2013;5(2):108–112. 

31. Andre P, Pietroni A, Faccione D, et al. Extended-spectrum beta-lactamases in Shigella flexneri from Argentina: first report of TOHO-1 outside Japan. Int J Antimicrob Agents. 2005;26(5):501–507. doi:10.1016/j.ijantimicag.2005.02.016 

32. Bialvaezi AZ, Pourtak D, Aghamali M, Asgharzadeh M, Gholizadeh P, Kafi HS. The prevalence of CTX-M-15 extended-spectrum beta-lactamases among Salmonella spp. and Shigella spp. isolated from three Iranian hospitals. Eur J Microbiol Immunol (Bpj). 2017;7(2):133–137. doi:10.1556/1886.2017.00004 

33. Kim JS, Kim J, Jeon SE, et al. Complete nucleotide sequence of the IncI1 plasmid pSH4469 encoding CTX-M-15 extended-spectrum beta-lactamase in a clinical isolate of Shigella sonnei from an outbreak in the Republic of Korea. Int J Antimicrob Agents. 2014;44(6):533–537. doi:10.1016/j.ijantimicag.2014.08.007 

34. Rashid H, Rahman M. Possible transfer of plasmid mediated extended-spectrum beta-lactamase producing Shigella strains in Israel, 2004–2008. Future Microbiol. 2014;9(10):1143–1150. doi:10.2217/fmb.14.153 

35. Thamizhmani R, Rhagavan R, Sugunan AP, Vijayachari P. VIM-1 extended-spectrum beta-lactamase-producing Shigella flexneri isolates from Andaman Islands. Future Microbiol. 2016;11:283–294. doi:10.2217/fmb.15.1150 

36. O’Hara K, Haruta S, Sawai T, Tsunoda M, Iyobe S. Novel metallo-beta-lactamase-mediated Shigella flexneri plasmid. FEMS Microbiol Lett. 1998;162(2):201–206. doi:10.1111/j.1574-6968.1998.tb12999.x 

37. Iyobe S, Kusadokoro H, Ozaki J, et al. Amino acid substitutions in a variant of IMP-1 metallo-beta-lactamase-producing Shigella flexneri plasmid. FEMS Microbiol Lett. 2000;176(2):197–202. doi:10.1111/j.1574-6968.2000.tb17072.x
56. Nuesch-Inderbinen M, Heini N, Zurfluh K, Althaus D, Hachler H, Stephan R. Shigella antimicrobial drug resistance mechanisms, 2004–2014. Emerg Infect Dis. 2016;22(6):1083–1085. doi:10.3201/eid2206.152088

57. Xue C, Cai J, Kang H, et al. Two novel mutations in parE among Shigella flexneri isolated from Jiangsu Province of China, 2016. Ann Transl Med. 2018;6(15):306. doi:10.21037/atm.2018.07.11

58. Dutta S, Kamawara Y, Ezaki T, Nair GB, Iida K, Yoshida S. Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant Shigella dysenteriae serotype 1 clinical isolates from Kolkata, India. Antimicrob Agents Chemother. 2005;49(4):1660–1661. doi:10.1128/aac.49.4.1660-1661.2005

59. Azmi IJ, Khajanchi BK, Akter F, et al. Fluoroquinolone resistance mechanisms of Shigella flexneri in the Hangzhou area of China. PLoS One. 2016;11(8):e0160290. doi:10.1371/journal.pone.0160290

60. Zhang WX, Chen HY, Tu LH, Xi MF, Chen M, Zhang J. Fluoroquinolone resistance mechanisms in Shigella isolates in Shanghai, China, between 2010 and 2015. Microb Drug Resist. 2019;25(2):212–218. doi:10.1089/mdr.2018.0113

61. Zhou C, Cao M, Zhou X, Li B, Zhang J. Epidemiic characterization and molecular typing of Shigella flexneri isolated from calves with diarrhoea in Northwest China. Antimicrob Resist Infect Control. 2017;6:435. doi:10.1186/s13327-017-0252-6

62. Bowen A, Hurd J, Hoover C, et al. Importation and domestic transmission of Shigella sonnei resistant to ciprofloxacin - United States, May 2014-February 2015. MMWR Morb Mortal Wkly Rep. 2015;64(12):318–320.

63. Pu XY, Pan JC, Wang HQ, Zhang W, Huang ZC, Gu YM. Characterization of fluoroquinolone-resistant Shigella flexneri in Hangzhou area of China. J Antimicrob Chemother. 2009;63(5):917–920. doi:10.1093/jac/dkp087

64. Hata M, Suzuki M, Matsumoto M, et al. Cloning of a novel gene for quinolone resistance from a transferable plasmid in Shigella flexneri 2b. Antimicrob Agents Chemother. 2005;49(2):801–803. doi:10.1128/aac.49.2.801-803.2005

65. Qin T, Qian H, Fan W, et al. Newest data on fluoroquinolone resistance mechanism of Shigella flexneri isolated in Jiangsu Province of China. Antimicrob Resist Infect Control. 2017;6:97. doi:10.1186/s13756-017-0249-1

66. Pu XY, Pan JC, Zhang W, Zhong X, Tian H, Gu YM. Quinolone resistance-determining region mutations and the plasmid-mediated quinolone resistance gene qnrS played important roles in decreased susceptibility to fluoroquinolones among Shigella isolates in southeast China between 1998 and 2013. Int J Antimicrob Agents. 2015;45(4):438–439. doi:10.1016/j.ijantimicag.2014.12.004

67. Pu XY, Gu Y, Li J, Song SJ, Lu Z. Characterization of the complete sequences and stability of plasmids carrying the genes aac(6’)-Ib-cr or qnr in Shigella flexneri in the Hangzhou area of China. World J Microbiol Biotechnol. 2018;34(6):72. doi:10.1007/s11274-018-2454-3

68. Ferjani S, Saidani M, Amine FS, Bouitiba-Ben Boubaker I. Prevalence and characterization of plasmid-mediated quinolone resistance genes in extended-spectrum beta-lactamase-producing Enterobacteriaceae in a Tunisian hospital. Microb Drug Resist. 2015;21(2):158–166. doi:10.1089/mdr.2014.0053

69. Yaghoubi S, Ranjbar S, Soltan Dallal MM, Shiri-Moz M, Shariandy MK. Frequency of mutations in quinolone resistance-determining regions and plasmid-mediated quinolone resistance in Shigella isolates recovered from pediatric patients in Tehran, Iran: an Overlooked Problem. Microb Drug Resist. 2018;24(6):699–706. doi:10.1089/mdr.2017.0155
81. Silver LL. Fosfomycin: mechanism and resistance. Cold Spring Harb Perspect Med. 2017;7(2):a025262. doi:10.1101/cshperspect.a025262

82. Fourmy D, Yoshizawa S, Puglisi JD. Paromomycin binding induces a local conformational change in the A-site of 16 S rRNA. J Mol Biol. 1998;277(2):333–345. doi:10.1006/jmbi.1997.1551

83. Shaw PC, Lian AC, Kam KM, Ling JM. Presence of stra-strb gene within a streptomycin-resistance operon in a clinical isolate of Shigella flexneri. Pathology. 1996;28(4):356–358. doi:10.1080/0031302960169344

84. McVernon CJ, White PA, Jones LA, et al. Molecular profiling of antimicrobial resistance genes. Antimicrob Agents Chemother. 2010;54(7):3061–3064. doi:10.1128/aac.01834-09

85. Iversen J, Sandvang D, Srijan P, et al. Molecular characterization of tetracycline resistance determinants in Shigella spp. and enteroinvasive Escherichia coli: characterization and dissemination of tet(A)-1. J Clin Microbiol. 2003;41(3):1023–1032. doi:10.1128/jcm.41.3.1023-1032.2003

86. Roberts MC. Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. FEMS Microbiol Rev. 1996;19(1):1–24. doi:10.1111/j.1574-6976.1996.tb00251.x

87. Wibberg D, Szczepanowski R, Eikmeyer F, Puhler A, Schluter A. Characterization of novel plasmid-mediated tetracycline resistance genes. J Antimicrob Chemother. 2013;69(10):6012–6021. doi:10.1093/jac/dkt1228

88. Hartman AB, Esselt II, Isenburger DW, Linder LE. Epidemiology of tetracycline resistance determinants in Shigella spp. and enteroinvasive Escherichia coli: characterization and dissemination of tet(A)-1. J Clin Microbiol. 2003;41(3):1023–1032. doi:10.1128/jcm.41.3.1023-1032.2003

89. Allue-Guardia A, Koenig SKK, Quiros P, Muniesa B, Bono JL, Eppinger M. Closed genome and comparative phylogenetic analysis of the clinical multidrug resistant Shigella sonnei strain 866. Genome Biol Evol. 2018;10(9):2241–2247. doi:10.1093/gbe/evy168

90. Pons MJ, Torrents de la Pena A, Mensa L, et al. Differences in tetracycline resistance determinant carriage among Shigella flexneri and Shigella sonnei are not related to different plasmid Inc-type carriage. J Glob Antimicrob Resist. 2018;13:131–134. doi:10.1016/j.jgar.2017.12.015

91. Mandomando I, Jaintilal D, Pons MJ, et al. Antimicrobial susceptibility and mechanisms of resistance in Shigella and Salmonella isolates from children under five years of age with diarrhea in rural Mozambique. Antimicrob Agents Chemother. 2009;53(6):2450–2454. doi:10.1128/aac.01282-08
144. Agle ME, Blaschek HP. Shigella: Survival on Produce and Biofilm Formation. Oxford: Blackwell Publishing Ltd. 2006:19–46.

145. Dorman MJ, Dorman CJ. Regulatory hierarchies controlling virulence gene expression in Shigella flexneri and vibrio cholerae. Front Microbiol. 2018;9:2686. doi:10.3389/fmicb.2018.02686

146. Ellaifi A, Abdallah FB, Lagha R, Harbi B, Bakhouf A. Biofilm production, adhesion and morphological alterations of Shigella spp. Under salt conditions. Annals of microbiology. 2011;61(4):741–747. doi:10.1007/s12213-010-0199-5

147. Olive AJ, Kenjale R, Espina M, Moore DS, Picking WL, Picking WD. Bile salts stimulate recruitment of IpDA to the Shigella flexneri surface, where it colocalizes with IpDA at the tip of the type III secretion needle. Infect Immun. 2007;75(5):2626–2629. doi:10.1128/IAI.01599-07

148. Barta ML, Guragain M, Adam P, et al. Identification of the bile salt binding site on IpDA from Shigella flexneri and the influence of ligand binding on IpDA structure. Proteins. 2012;80(3):935–945.

149. Xu D, Zhang W, Zhang B, Liao C, Shao Y. Characterization of a biofilm-forming Shigella flexneri phenotype due to deficiency in Hes biosynthesis. PeerJ. 2016;4:e2178. doi:10.7717/peerj.2178

150. Filho-Lima JV, Vieira EC, Nicoli JR. Antagonistic effect of Lactobacillus acidophilus, Saccharomyces boulardii and Escherichia coli combinations against experimental infections with Shigella flexneri and Salmonella enteritidis subs. typhimurium in gnotobiotic mice. J Appl Microbiol. 2000;88(3):365–370. doi:10.1046/j.1365-2672.2000.00973.x

151. Zhang Y, Zhang L, Du M, et al. Antimicrobial activity against Shigella sonnei and probiotic properties of wild lactobacilli from fermented food. Microbiol Res. 2011;167(1):27–31. doi:10.1016/j.micres.2011.02.006

152. Moothy G, Murali MR, Niranjali Devaraj S. Lactobacilli inhibit Shigella dysenteriae 1 induced pro-inflammatory response and cytotoxicity in host cells via impediment of Shigella-host interactions. Dig Liver Dis. 2010;42(1):33–39. doi:10.1016/j.dld.2009.04.021

153. Zhang YC, Zhang LW, Ma W, et al. Screening of probiotic lactobacilli for inhibition of Shigella sonnei and the macromolecules involved in inhibition. Anaerobe. 2012;18(5):498–503. doi:10.1016/j.anaerobe.2012.08.007

154. Mirnejadi R, Vahdati AR, Rashidiani J, Erfani M, Piranfar V. The antimicrobial effect of lactobacillus casei culture supernatant against multiple drug resistant clinical isolates of Shigella sonnei and Shigella flexneri in vitro. Iran Red Crescent Med J. 2013;15(2):122–126. doi:10.5812/ircmj.7454

155. Ayeni AO, Ayeni FA. Antagonistic effects of lactic and acetic acid bacteria on Shigella sp. SS10 in co-culture. TAP Preventive Medicine Bulletin. 2016;15(1):27–31. doi:10.5455/pmb.1-1438753866

156. Muny KL, Chen X, Kelly CP, McCormick BA. Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events. Am J Physiol Gastrointest Liver Physiol. 2008;294(3):G599–G609. doi:10.1152/ajpgi.00391.2007

157. Rene K, Hortense G, Pascal W, et al. Activity of aqueous ethanol extract of Euphorbia prostrata ait on Shigella dysenteriae type 1-induced diarrhoea in rats. BMC Complement Altern Med. 2013;13:211. doi:10.1186/1472-6882-13-211

158. Hussain SA, Patil GR, Reddi S, et al. Aloe vera (Aloe barbadensis Miller) supplemented probiotic lassi prevents Shigella infection from epithelial barrier into systemic blood flow in mice model. Microb Pathog. 2017;102:143–147. doi:10.1016/j.micpath.2016.11.023

159. Kiran S, Ratho RK, Sharma P, Harjai K, Capalash N, Tiwari RP. Effect of black tea (Camellia sinensis) on virulence traits of clinical isolates of Shigella dysenteriae and Escherichia coli EPEC P2 1265 strains. Eur Food Res Technol. 2010;231(5):763–770. doi:10.1007/s00217-010-1328-1

160. Kouitchou LB, Tamesse JL, Kouam J. The anti-shigellosis activity of the methanol extract of ptericolora nitida on Shigella dysenteriae type 1 induced diarrhoea in rats. BMC Complement Altern Med. 2013;13:211. doi:10.1186/1472-6882-13-211
178. Phalipon A, Costachel C, Grandjean C, et al. Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine. J Immunol. 2006;176(3):1686–1694. doi:10.4049/jimmunol.176.3.1686

179. Ranallo RT, Fonseka S, Boren TL, et al. Two live attenuated Shigella flexneri 2a strains WRS72G12 and WRS72G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates. Vaccine. 2012;30(34):5159–5171. doi:10.1016/j.vaccine.2012.05.003

180. Raqi R, Sarker P, Zaman K, et al. A phase I trial of WRS1, a Shigella sonnei live oral vaccine in Bangladeshis adults and children. Hum Vaccin Immunother. 2019;1–12. doi:10.1080/21645515.2019.1575165.

181. Heine SJ, Diaz-McNair J, Andar AU, et al. Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes. J Immunol. 2014;192(4):1630–1640. doi:10.4049/jimmunol.1302743

182. DeLaine BC, Wu T, Gressel CL, et al. Characterization of a multi-component live, attenuated Shigella flexneri vaccine. Pathog Dis. 2016;74(5). doi:10.1093/femsdp/ftw034

183. Toapanta FR, Bernal PJ, Kotloff KL, Levine MM, Sztein MB. Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftriaxone. Antimicrob Agents Chemother. 2009;53(1):69–74. doi:10.1128/aac.00227-08

184. Mitobe J, Sinha R, Mitra S, et al. An attenuated Shigella mutant for mucosal protection against Shigella dysenteriae type-1: evaluation of oral and intranasal route of administration. J Infect Dis. 2017;215(2):259–268. doi:10.1093/infdis/jiw528

185. Mitobe J, Sinha R, Mitra S, et al. An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross-protection against Shigella strains of broad serotype.PLoS Negl Trop Dis. 2017;11(7):e005728. doi:1371/journal.pntd.005728

186. Wu Y, Chakravarty S, Li M, Wai TT, Hoffman SL, Sim BK. Development of a live attenuated bivalent oral vaccine against Shigella sonnei Shigellosis and Typhoid Fever. J Infect Dis. 2017;215(2):259–268. doi:10.1093/infdis/jiw528

187. Nagono Y, Nagano N, Wachino J, Ishikawa K, Arakawa Y. Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftriaxone. Antimicrob Agents Chemother. 2009;53(1):69–74. doi:10.1128/aac.00227-08

188. Schumacher H, Nir M, Mansa B, Grassy A. beta-lactamases in Shigella. Apiny. 1992;100(10):954–956.

189. Qin T, Bi R, Fan W, Kang H, Ma P, Gu B. Novel mutations in quinolone resistance-determining regions of gyrA, gyrB, parC, and parE in Shigella flexneri clinical isolates from eastern Chinese populations between 2001 and 2011. Eur J Clin Microbiol Infect Dis. 2016;35(12):2037–2045. doi:10.1007/s10096-016-2761-2

190. Obiero CW, Ndiaye AGW, Scire AS, et al. A phase 2a randomized clinical evaluation of a trivalent, formalin-inactivated Shigella dysenteriae type-1 vaccine candidate. Vaccine. 2008;26(26):3291–3296. doi:10.1016/j.vaccine.2008.03.079

191. Rahman KM, Arifeen SE, Zaman K, et al. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh. Vaccine. 2011;29(6):1347–1354. doi:10.1016/j.vaccine.2010.10.035

192. Chowdhury FM, Rahman MZ, Sarkar MMH, et al. Protection against shigellosis caused by Shigella dysenteriae serotype 4 in guinea pigs using Escherichia albiorchid DM104 as a live vaccine candidate strain. Acta Microb Immunol Hung. 2017;64(2):151–164. doi:10.1556/03.64.2017.015

193. McKenzie R, Venkatesan MM, Wolf MK, et al. Safety and immunogenicity of WRS1, a live attenuated Shigella dysenteriae type 1 vaccine candidate. Vaccine. 2008;26(26):3291–3296. doi:10.1016/j.vaccine.2008.03.079

194. Taneja N, Mewara A, Kumar A, Verma G, Sharma M. Cephalosporin-resistant Shigella sonnei Shigellosis and Typhoid Fever. Amer J Trop Med Hyg. 1972;21:469.

195. Nagano Y, Wachino J, Ishikawa K, Arakawa Y. Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftriaxone. Antimicrob Agents Chemother. 2009;53(1):69–74. doi:10.1128/aac.00227-08

196. Schumacher H, Nir M, Mansa B, Grassy A. beta-lactamases in Shigella. Apiny. 1992;100(10):954–956.

197. Qin T, Bi R, Fan W, Kang H, Ma P, Gu B. Novel mutations in quinolone resistance-determining regions of gyrA, gyrB, parC, and parE in Shigella flexneri clinical isolates from eastern Chinese populations between 2001 and 2011. Eur J Clin Microbiol Infect Dis. 2016;35(12):2037–2045. doi:10.1007/s10096-016-2761-2

198. Chowdhury FM, Rahman MZ, Sarkar MMH, et al. Protection against shigellosis caused by Shigella dysenteriae serotype 4 in guinea pigs using Escherichia albiorchid DM104 as a live vaccine candidate strain. Acta Microb Immunol Hung. 2017;64(2):151–164. doi:10.1556/03.64.2017.015

199. McKenzie R, Venkatesan MM, Wolf MK, et al. Safety and immunogenicity of WRS1, a live attenuated Shigella dysenteriae type 1 vaccine candidate. Vaccine. 2008;26(26):3291–3296. doi:10.1016/j.vaccine.2008.03.079

200. Rahman KM, Arifeen SE, Zaman K, et al. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh. Vaccine. 2011;29(6):1347–1354. doi:10.1016/j.vaccine.2010.10.035
208. Hatz CF, Bally B, Rohrer S, et al. Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: a single blind, partially randomized phase I study. *Vaccine*. 2015;33(36):4594–4601. doi:10.1016/j.vaccine.2015.06.102

209. Pozsgay V, Chu C, Pannell L, Wolfe J, Robbins JB, Schneerson R. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. *Proc Natl Acad Sci U S A*. 1999;96(9):5194–5197. doi:10.1073/pnas.96.9.5194

210. Mitra S, Sinha R, Mitobe J, Koley H. Development of a cost-effective vaccine candidate with outer membrane vesicles of a tolA-disrupted Shigella boydii strain. *Vaccine*. 2016;34(15):1839–1846. doi:10.1016/j.vaccine.2016.02.018